<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">107039</article-id>
<article-id pub-id-type="doi">10.7554/eLife.107039</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.107039.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.4</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Cell Biology</subject>
</subj-group>
</article-categories><title-group>
<article-title>CCDC32 stabilizes clathrin-coated pits and drives their invagination</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Ziyan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Changsong</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Zheng</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Peiliu</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Yueping</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Han</surname>
<given-names>Lu</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peng</surname>
<given-names>Linyuan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Xiangying</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pak</surname>
<given-names>John</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Svitkina</surname>
<given-names>Tatyana</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Schmid</surname>
<given-names>Sandra L</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a5">5</xref>
<email>sandra.schmid@czbiohub.org</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2423-101X</contrib-id>
<name>
<surname>Chen</surname>
<given-names>Zhiming</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<email>Zhiming.Chen@usc.edu.cn</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03mqfn238</institution-id><institution>NHC Key Laboratory of Birth Defect Research and Prevention, MOE Key Laboratory of Rare Pediatric Diseases, Institute of Cytology and Genetics of School of Basic Medical Sciences &amp; Department of Clinical Laboratory of The First Affiliated Hospital, Hengyang Medical School, University of South China</institution></institution-wrap>, <city>Hengyang</city>, <country country="CN">China</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Department of Biology, University of Pennsylvania</institution></institution-wrap>, <city>Philadelphia</city>, <country country="US">United States</country></aff>
<aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00s7tkw17</institution-id><institution>Fuzhou Institute of Oceanography, College of Geography and Oceanography, Minjiang University</institution></institution-wrap>, <city>Fuzhou</city>, <country country="CN">China</country></aff>
<aff id="a4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00knt4f32</institution-id><institution>Chan Zuckerberg Biohub</institution></institution-wrap>, <city>San Francisco</city>, <country country="US">United States</country></aff>
<aff id="a5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05byvp690</institution-id><institution>Department of Cell Biology, University of Texas Southwestern Medical Center</institution></institution-wrap>, <city>Dallas</city>, <country country="US">United States</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Lu</surname>
<given-names>Lei</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Nanyang Technological University</institution>
</institution-wrap>
<city>Singapore</city>
<country country="SG">Singapore</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Campelo</surname>
<given-names>Felix</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>Universitat Pompeu Fabra</institution>
</institution-wrap>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="coi-statement"><p>Competing interests: No competing interests declared</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2025-06-11">
<day>11</day>
<month>06</month>
<year>2025</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2025-08-15">
<day>15</day>
<month>08</month>
<year>2025</year>
</pub-date>
<volume>14</volume>
<elocation-id>RP107039</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2025-04-25">
<day>25</day>
<month>04</month>
<year>2025</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2025-04-29">
<day>29</day>
<month>04</month>
<year>2025</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.06.26.600785"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2025-06-11">
<day>11</day>
<month>06</month>
<year>2025</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.107039.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.107039.1.sa4">eLife Assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.107039.1.sa3">Reviewer #1 (Public review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.107039.1.sa2">Reviewer #2 (Public review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.107039.1.sa1">Reviewer #3 (Public review):</self-uri>
<self-uri content-type="author-comment" xlink:href="https://doi.org/10.7554/eLife.107039.1.sa0">Author response:</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2025, Yang et al</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Yang et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-107039-v2.pdf"/>
<abstract>
<title>Abstract</title><p>Clathrin-mediated endocytosis (CME) is essential for maintaining cellular homeostasis. Previous studies have reported more than 50 CME accessory proteins; however, the mechanism driving the invagination of clathrin-coated pits (CCPs) remains elusive. We show by quantitative live cell imaging that siRNA-mediated knockdown of CCDC32, a poorly characterized endocytic accessory protein, leads to the accumulation of unstable flat clathrin assemblies. CCDC32 interacts with the α-appendage domain (AD) of AP2 <italic>in vitro</italic> and with full length AP2 complexes in cells. Deletion of aa78-98 in CCDC32, corresponding to a predicted α-helix, abrogates AP2 binding and CCDC32’s early function in CME. Furthermore, clinically observed nonsense mutations in CCDC32, which result in C-terminal truncations that lack aa78-98, are linked to the development of cardio-facio-neuro-developmental syndrome (CFNDS). Overall, our data demonstrate the function of a novel endocytic accessory protein, CCDC32, in regulating CCP stabilization and invagination, critical early stages of CME.</p>
</abstract>
<abstract abstract-type="teaser">
<title>Summary</title>
<p>We show that CCDC32, a poorly studied and functionally ambiguous protein, binds to AP2 and regulates CCP stabilization and invagination. Clinically observed mutations in CCDC32 lose their ability to interact with AP2 likely contributing to the development of cardio-facio-neuro-developmental syndrome.</p>
</abstract>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>The manuscript have been revised according to reviews from eLife. Some texts have been modified to deliver the message clearly.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
    <p>Clathrin-mediated endocytosis (CME) regulates nutrient uptake and maintains the activity of transmembrane transporters and is thus, essential for maintaining cellular homeostasis (<xref ref-type="bibr" rid="c31">Kaksonen and Roux, 2018</xref>; <xref ref-type="bibr" rid="c32">Kirchhausen et al., 2014</xref>; <xref ref-type="bibr" rid="c40">McMahon and Boucrot, 2011</xref>; <xref ref-type="bibr" rid="c44">Mettlen et al., 2018</xref>). Malfunctions of CME are strongly associated with neurological diseases, cardiovascular diseases, and cancers (<xref ref-type="bibr" rid="c7">Blue et al., 2018</xref>; <xref ref-type="bibr" rid="c15">DeMari et al., 2016</xref>; <xref ref-type="bibr" rid="c16">Elkin et al., 2015</xref>; <xref ref-type="bibr" rid="c18">Gilles Moulay, 2019</xref>; <xref ref-type="bibr" rid="c23">Hamdan et al., 2017</xref>; <xref ref-type="bibr" rid="c39">Manti et al., 2019</xref>; <xref ref-type="bibr" rid="c58">Sznajder and Swanson, 2019</xref>; <xref ref-type="bibr" rid="c68">Wu and Yao, 2009</xref>). CME occurs via the assembly of clathrin triskelia into clathrin-coated pits (CCPs) that invaginate to form clathrin-coated vesicles (CCVs) (<xref ref-type="bibr" rid="c31">Kaksonen and Roux, 2018</xref>; <xref ref-type="bibr" rid="c44">Mettlen et al., 2018</xref>; <xref ref-type="bibr" rid="c53">Smith and Smith, 2022</xref>). During CCP maturation, successful invagination of the clathrin coat and its underlying membrane is a key step that determines whether nascent CCPs are productive or abortive (<xref ref-type="bibr" rid="c3">Aguet et al., 2013</xref>; <xref ref-type="bibr" rid="c5">Baschieri et al., 2020</xref>; <xref ref-type="bibr" rid="c10">Chen and Schmid, 2020</xref>; <xref ref-type="bibr" rid="c67">Wang et al., 2020</xref>). Although more than 50 endocytic accessory proteins (EAPs) have been reported to be involved in the progression of CME (<xref ref-type="bibr" rid="c6">Bhave et al., 2020</xref>; <xref ref-type="bibr" rid="c10">Chen and Schmid, 2020</xref>; <xref ref-type="bibr" rid="c32">Kirchhausen et al., 2014</xref>; <xref ref-type="bibr" rid="c40">McMahon and Boucrot, 2011</xref>; <xref ref-type="bibr" rid="c42">Merrifield and Kaksonen, 2014</xref>; <xref ref-type="bibr" rid="c54">Sochacki et al., 2017</xref>; <xref ref-type="bibr" rid="c60">Taylor et al., 2011</xref>; <xref ref-type="bibr" rid="c61">Traub, 2011</xref>), the mechanism of CCP invagination remains elusive, i.e. which accessory proteins are required and how do they regulate CCP invagination?</p>
<p>Coiled-coil domain-containing protein 32 (CCDC32), also known as gene <italic>C15orf57</italic>, is a small, 185 amino acids (aa) protein that has been poorly studied and whose function was unknown. Clinical genome sequencing of three patients with cardio-facio-neuro-developmental syndrome (CFNDS) revealed three homozygous nonsense mutations that only express the first 9, 54 and 80aa of CCDC32, respectively (<xref ref-type="bibr" rid="c1">Abdalla et al., 2022</xref>; <xref ref-type="bibr" rid="c24">Harel et al., 2020</xref>). How these loss-of-function mutations result in CFNDS remains unknown.</p>
<p>A genome-wide co-essential modules study (<xref ref-type="bibr" rid="c65">Wainberg et al., 2021</xref>) suggested a functional correlation between CCDC32 and AP2, whose interactions were also implied by affinity purification-mass spectroscopy (AP-MS) analysis (<xref ref-type="bibr" rid="c11">Cho et al., 2022</xref>) and co-immunoprecipitation (co-IP) assays (<xref ref-type="bibr" rid="c65">Wainberg et al., 2021</xref>). In addition, depletion of CCDC32 was observed to inhibit transferrin uptake, suggesting a role in CME (<xref ref-type="bibr" rid="c65">Wainberg et al., 2021</xref>). More recently, and while this paper was under review, Wan et al. (<xref ref-type="bibr" rid="c66">Wan et al., 2024</xref>) reported an essential role for CCDC32 as a co-chaperone with AAGAB (alpha and gamma adaptin binding protein) in the assembly of AP2 complexes. The authors showed that in CRISRP-mediated CCDC32 knockout cells, AP2 complexes were severely depleted, and CME was strongly inhibited. They further showed <italic>in vitro,</italic> that CCDC32 was recruited to the AAGAB:α:σ2 hemicomplex, where it displaced AAGAB, recruited µ2 and β2 subunits to assemble the mature AP2 complex and then was released. They were unable to detect interactions between a C-terminally tagged CCDC32 and the mature AP2 complex (<xref ref-type="bibr" rid="c66">Wan et al., 2024</xref>).</p>
<p>Using a combination of biochemistry, quantitative live cell imaging and ultrastructure electron microscopy, we report that a functional N-terminally tagged CCDC32 interacts with the intact AP2 complex and is recruited to CCPs. siRNA knockdown of CCDC32 inhibits CCP invagination and stabilization, without impacting the levels of AP2 expression. Thus, we demonstrate a second, critical role for CCDC32 in regulating early stages of CME by regulating the stabilization and invagination of CCPs.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>CCDC32 is recruited to CCPs</title>
    <p>We first explored a direct role for CCDC32 in CME by testing if and when CCDC32 is recruited to CCPs. ARPE-HPV cells that stably express mRuby-clathrin light chain a (mRuby-CLCa) and siRNA-resistant, N-terminally GFP tagged full-length CCDC32 (eGFP-CCDC32(FL)) were generated (<xref ref-type="fig" rid="figs1">Fig. S1</xref>) and imaged using Total Internal Reflection Fluorescence Microscopy (TIRFM). In addition to diffuse staining across the inner plasma membrane (PM) surface, suggestive of direct membrane binding, we also observed colocalization of eGFP-CCDC32(FL) and mRuby-CLCa (<xref rid="fig1" ref-type="fig">Fig. 1A</xref>) at clathrin coated pits.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1:</label>
<caption><title>CCDC32 is recruited to clathrin-coated pits.</title>
<p><bold>(A)</bold> Representative TIRFM images of ARPE-HPV cells that stably express mRuby-CLCa and eGFP-CCDC32(FL). This dual channel imaging was conducted without siRNA-mediated knockdown. White arrows point to colocalized CLCa and CCDC32 clusters. White ROI is magnified on the right. Scale bar = 5µm. <bold>(B)</bold> Cohort-averaged fluorescence intensity traces of CCPs (marked with mRuby-CLCa) and CCP-enriched eGFP-CCDC32(FL). 51.3±8.2% of analyzed CCPs showed eGFP-CCDC32(FL) recruitment. Number of tracks analyzed: 23699. <bold>(C)</bold> Lifetime distributions of all CCPs, CCPs with eGFP-CCDC32 recruitment, and CCPs without eGFP-CCDC32 recruitment.</p></caption>
<graphic xlink:href="600785v4_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
    <p>Furthermore, cohort-averaged fluorescence intensity traces were obtained using time-lapse imaging and primary (mRuby-CLCa)/subordinate (eGFP-CCDC32) tracking powered by cmeAnalysis (<xref ref-type="bibr" rid="c3">Aguet et al., 2013</xref>; <xref ref-type="bibr" rid="c9">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="c28">Jaqaman et al., 2008</xref>). As a negative control, ARPE-HPV cells that stably express mRuby-CLCa and eGFP showed neither diffuse PM staining nor eGFP recruitment to CCPs (<xref ref-type="fig" rid="figs2">Fig. S2</xref>), whereas more than half of analyzed CCPs were observed to recruit CCDC32. The recruitment curve of CCDC32 follows the assembly of clathrin on CCPs (<xref rid="fig1" ref-type="fig">Fig. 1B</xref>). Importantly, compared to CCDC32-positive CCPs, those that fail to recruit eGFP-CCDC32 exhibited significantly shorter, and exponentially decaying lifetimes, previously shown to be characteristic of abortive CCPs (<xref rid="fig1" ref-type="fig">Fig. 1C</xref>) (<xref ref-type="bibr" rid="c3">Aguet et al., 2013</xref>). Together these data establish that the early recruitment, along with clathrin, of CCDC32 to nascent CCPs regulates their maturation and lifetimes.</p>
</sec>
<sec id="s2b">
<title>CCDC32 depletion inhibits transferrin receptor (TfnR) uptake and CCP formation</title>
<p>To gain further insight into the function of CCDC32 in CME, we next examined the effects of siRNA-mediated knockdown of CCDC32 on CME and CCP dynamics. In agreement with the previous observation (<xref ref-type="bibr" rid="c65">Wainberg et al., 2021</xref>), siRNA-mediated knockdown of CCDC32 in ARPE-HPV cells, which resulted in an ∼60% depletion of CCDC32 (<xref rid="fig2" ref-type="fig">Fig. 2A,B</xref>), reduced the cellular uptake efficiency of TfnR (<xref rid="fig2" ref-type="fig">Fig. 2C</xref>).</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2:</label>
<caption><title>CCDC32 depletion inhibits Transferrin Receptor (TfnR) uptake and CCP maturation.</title><p><bold>(A)</bold> Immunoblotting (IB) shows efficient CCDC32 knockdown in ARPE-HPV cells by siRNA treatment. <bold>(B)</bold> Quantified knockdown efficiency (∼60%) of CCDC32 (n=8). <bold>(C)</bold> Measurements of the uptake efficiency of TfnR (n=8). % of surface bound = Internalized/Surface bound*100%. Error bars in (B-C) indicate standard deviations. <bold>(D-E)</bold> Representative single frame images from TIRFM videos (7.5 min/video, 1 frame/s, see videos 1 and 2) and corresponding kymographs from region indicated by yellow lines of ARPE-HPV eGFP-CLCa cells treated with (D) control siRNA or (E) CCDC32 siRNA. Scale bars = 5µm. <bold>(F-H)</bold> Effect of CCDC32 knockdown on the initiation rates of (F) all CCSs and (G) <italic>bona fide</italic> CCPs, as well as (H) the % of <italic>bona fide</italic> CCPs. Each dot represents a video (n=11). Statistical analysis of the data in (F-H)) is the Wilcoxon rank sum test, ***, p ≤ 0.001. <bold>(I)</bold> Lifetime distribution of <italic>bona fide</italic> CCPs. Data presented were obtained from a single experiment (n = 11 videos for each condition) that is representative of 3 independent repeats. Number of dynamic tracks analyzed: 125897 for siControl and 105313 for siCCDC32. Shadowed area indicates 95% confidential interval.</p></caption>
<graphic xlink:href="600785v4_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
    <p>A recent study reported that CCDC32 functions as an essential chaperone for AP2 complex assembly and that CRISPR-mediated knockout of CCDC32 led to a severe decrease in AP2 (<xref ref-type="bibr" rid="c66">Wan et al., 2024</xref>). Under our conditions of CCDC32 knockdown, we did not detect any decrease in protein levels of the AP2 complex (<xref ref-type="fig" rid="figs3">Fig. S3A,B</xref>), suggesting that the residual CCDC32 was fully capable of fulfilling this catalytic function.</p>
    <p>To further define which stages of CME were dependent on CCDC32, we knocked down CCDC32 in ARPE-HPV cells that stably express eGFP-CLCa and employed quantitative live-cell TIRFM to visualize and analyze CCP dynamics (<xref ref-type="bibr" rid="c45">Mettlen and Danuser, 2014</xref>). The videos and kymographs of time-lapse imaging showed that CCDC32 depletion resulted in the formation of brighter, static clathrin-coated structures (CCSs) (<xref rid="fig2" ref-type="fig">Fig. 2D,E</xref> &amp; Videos 1,2) that dominate the images. These have been seen under other perturbation conditions (<xref ref-type="bibr" rid="c3">Aguet et al., 2013</xref>; <xref ref-type="bibr" rid="c9">Chen et al., 2020</xref>) and reflect the accumulation of CCPs that are either larger, flatter or both. However, we also noted a subpopulation of dynamic CCPs (arrows, <xref rid="fig2" ref-type="fig">Fig. 2E</xref>) that were visually obscured by bright static CCSs, yet represent the majority of total CCSs detected. Indeed, despite the deceptive nature of the images, which we have previously reported (<xref ref-type="bibr" rid="c9">Chen et al., 2020</xref>), the percentage of static CCSs (lifetime &gt; 150s), as determined by unbiased quantitative analysis, was only 7.9% (<xref ref-type="fig" rid="figs4">Fig. S4</xref>).</p>
<p>To quantify the dynamic behaviors of CCPs, we performed cmeAnalysis (<xref ref-type="bibr" rid="c3">Aguet et al., 2013</xref>; <xref ref-type="bibr" rid="c28">Jaqaman et al., 2008</xref>; <xref ref-type="bibr" rid="c37">Loerke et al., 2011</xref>) and DASC (disassembly asymmetry score classification) (<xref ref-type="bibr" rid="c67">Wang et al., 2020</xref>), which together provide a comprehensive and unbiased characterization of CCP intermediates and CME progression when CCDC32 was depleted. DASC, which measures fluctuations of clathrin-assembly/disassembly to accurately distinguish abortive from productive CCPs (<xref ref-type="bibr" rid="c67">Wang et al., 2020</xref>), revealed an increased rate of nascent clathrin assembly, reported as the initiation rate of clathrin-coated structures (CCSs) (<xref rid="fig2" ref-type="fig">Fig. 2F</xref>), but a reduced rate of <italic>bona fide</italic> CCP initiation (<xref rid="fig2" ref-type="fig">Fig. 2G</xref>) and a correspondingly lower percentage of stable, <italic>bona fide</italic> CCPs (CCP%) (<xref rid="fig2" ref-type="fig">Fig. 2H</xref>), which are both brighter and longer-lived than abortive CCPs (<xref ref-type="bibr" rid="c67">Wang et al., 2020</xref>). Together these data reveal an early defect in the growth and stabilization of nascent clathrin assemblies leading to an increase in the fraction of abortive CCPs. Importantly, the remaining dynamic population of <italic>bona fide</italic> CCPs exhibited shorter lifetimes upon CCDC32 knockdown (<xref rid="fig2" ref-type="fig">Fig 2I</xref>), indicating their more rapid maturation.</p>
<p>Together these results demonstrate that CCDC32 is an important endocytic accessory protein involved in CCP stabilization and maturation. Strikingly, despite the profound effects of CCDC32 depletion on CCP dynamics, the efficiency of TfnR uptake was only marginally affected (<xref rid="fig2" ref-type="fig">Fig. 2C</xref>). These paradoxical effects are typical for endocytic accessory proteins and indicative of their functional redundancy and/or the induction of compensatory mechanisms, including in this case, the observed increased rate of CCS assembly (<xref rid="fig2" ref-type="fig">Fig. 2E</xref>) and the more rapid maturation of <italic>bona fide</italic> CCPs (<xref rid="fig2" ref-type="fig">Fig 2I</xref>) (<xref ref-type="bibr" rid="c3">Aguet et al., 2013</xref>; <xref ref-type="bibr" rid="c6">Bhave et al., 2020</xref>; <xref ref-type="bibr" rid="c67">Wang et al., 2020</xref>).</p>
</sec>
<sec id="s2c">
<title>CCDC32 regulates CCP invagination</title>
<p>During CCP maturation, successful invagination of the clathrin coat and its underlying membrane has been identified as a key step that determines the fate of CCPs (<xref ref-type="bibr" rid="c3">Aguet et al., 2013</xref>; <xref ref-type="bibr" rid="c67">Wang et al., 2020</xref>). To determine whether CCDC32 regulates CCP invagination, we first used Epifluorescence (Epi)-TIRF microscopy to measure CCP invagination in live cells (<xref rid="fig3" ref-type="fig">Fig. 3A</xref>). In this approach, time-lapse Epi and TIRF fluorescence signals were near-simultaneously acquired for ARPE-HPV eGFP-CLCa cells (<xref rid="fig3" ref-type="fig">Fig. 3B</xref>) and analyzed using primary (TIRF-channel)/subordinate (Epi-channel) tracking powered by cmeAnalysis (<xref ref-type="bibr" rid="c67">Wang et al., 2020</xref>). The resulting Epi and TIRF fluorescence intensity traces of CCPs with similar lifetimes were then aligned and averaged to yield intensity cohorts, which were further log-transformed to give average traces of the invagination depth (Δz) of the CCPs’ center-of-mass (<xref rid="fig3" ref-type="fig">Fig. 3A,C</xref>). Here, we chose to present CCPs with lifetimes of 25-35s because they represent the invagination behavior of the most frequent tracks in control cells (<xref rid="fig2" ref-type="fig">Fig. 2H</xref>). CCDC32 knockdown strongly inhibited CCP invagination (<xref rid="fig3" ref-type="fig">Fig. 3C</xref>), suggesting a key role for CCDC32 in regulating this critical early stage in CME.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3:</label>
<caption><title>CCDC32 depletion inhibits CCP invagination.</title>
<p><bold>(A)</bold> Scheme of Epi-TIRF microscopy for measuring the invagination of CCPs using primary/subordinate tracking. Δz(t) denotes the invagination depth of CCPs over time. <italic>I<sub>E</sub></italic> and <italic>I<sub>T</sub></italic> denotes the cohort-averaged fluorescence intensity from Epi and TIRF channels, respectively. <italic>k<sub>E</sub></italic> and <italic>k<sub>T</sub></italic> are the initial growth rate for the Epi and TIRF channel signals, respectively. <italic>I<sub>O</sub></italic> is an additive correction factor. ‘*’ indicates the mass center of clathrin coat. h=115nm is the evanescent depth of TIRF field, see more detail in ref.(<xref ref-type="bibr" rid="c50">Saffarian and Kirchhausen, 2008</xref>; <xref ref-type="bibr" rid="c67">Wang et al., 2020</xref>). <bold>(B)</bold> Representative Epi and TIRF microscopy images. Scale bars = 10µm. <bold>(C)</bold> Epi-TIRF microscopy analysis shows that knockdown CCDC32 strongly inhibited CCP invagination. Top: Cohort-averaged CCP fluorescence intensity traces from Epi and TIRF channels; bottom: calculated Δ<italic>z</italic>(<italic>t</italic>)/<italic>h</italic> curves. Data presented were obtained from n = 12 videos for each condition. Number of CCP tracks analyzed to obtain the Δ<italic>z</italic>/<italic>h</italic> curves: 5998 for siControl and 4418 for siCCDC32. Shadowed area indicates 95% confidential interval.</p></caption>
<graphic xlink:href="600785v4_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
    <p>To independently validate that CCDC32 regulates CCP invagination, we next examined the clathrin-coated structures (CCSs) at higher resolution using Platinum Replica Electron Microscopy (PREM) (<xref ref-type="bibr" rid="c57">Svitkina, 2017</xref>). Strikingly, CCDC32 knockdown resulted in a substantial increase in the number of flat CCSs (<xref rid="fig4" ref-type="fig">Fig. 4A-C</xref>, pseudo-colored blue in panel B, see also <xref ref-type="fig" rid="figs5">Fig. S5A-C</xref>) and a corresponding higher occupancy of CCSs on the PM (<xref rid="fig4" ref-type="fig">Fig. 4E</xref>; <xref ref-type="fig" rid="figs5">Fig. S5D</xref>), consistent with TIRFM and Epi-TIRF microscopy observations. While the flat CCSs we detected in CCDC32 knockdown cells were significantly larger than in control cells (<xref rid="fig4" ref-type="fig">Fig. 4D</xref>, mean diameter of 147 nm vs. 127 nm, respectively), they are much smaller than typical long-lived flat clathrin lattices (d≥300 nm) (<xref ref-type="bibr" rid="c21">Grove et al., 2014</xref>). Indeed, the surface area of the flat CCSs that accumulate in CCDC32 KD cells (mean ∼1.69 x 10<sup>4</sup> nm<sup>2</sup>) remains significantly less than the surface area of an average 100 nm diameter CCV (∼3.14 x 10<sup>4</sup> nm<sup>2</sup>). Thus, we refer to these structures as ‘flat clathrin assemblies’ because they are neither curved ‘pits’ nor large ‘lattices’. Rather, the flat clathrin assemblies represent early, likely defective, intermediates in CCP formation. Importantly, while significantly decreased in both number and size, dome-shaped (green) and spherical (orange) CCSs were still detected, likely corresponding to intermediates within the larger subpopulation of dynamic, <italic>bona fide</italic> CCPs able to maintain TfnR uptake (<xref rid="fig4" ref-type="fig">Fig. 4A-D</xref>; <xref ref-type="fig" rid="figs5">Fig. S5A-C</xref>). The PREM results provide high resolution structural data supporting a critical role for CCDC32 in regulating CCP invagination.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4:</label>
<caption><title>Flat clathrin lattices accumulate in cells depleted of CCDC32.</title><p>(A-B) Representative PREM images of ARPE19 cells treated with (A) control siRNA or (B) CCDC32 siRNA showing flat (blue), dome-shaped (green) and spherical (orange) CCSs. Scale bars = 200nm. <bold>(C-E)</bold> Quantification of the clathrin-coated structures (CCSs) by (C) shape category, (D) the CCS projection area, and (E) the CCS occupancy on the plasma membrane (PM). Each dot in (E) represents an individual fragment of the PM; the number of cell membrane fragments analyzed is 38 for siControl cells and 35 for siCCDC32 cells from two independent experiments, n = number of CCS. Statistical tests were performed using Mann-Whiney test (D) or unpaired t-test (E). For the Box and whisker plots in (D) and (E), the box extends from the 25th to 75th percentiles, the line in the middle of the box is plotted at the median, and the “+” indicates the mean.</p></caption>
<graphic xlink:href="600785v4_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2d">
<title>CCDC32 interacts with the AP2 α-appendage domain</title>
    <p>Next, we explored the mechanism of CCDC32 recruitment to CCPs. The adaptor AP2, which is essential for CCP and CCV formation, is a heterotetramer consisting of α, β2, μ2, and σ2 subunits (<xref rid="fig5" ref-type="fig">Fig. 5A</xref>). A previous study had reported interactions between overexpressed σ2-mCherry and CCDC32-GFP (<xref ref-type="bibr" rid="c65">Wainberg et al., 2021</xref>), but had not demonstrated interactions with the native AP2 complex. A more recent study reported that C-terminally tagged CCDC32 interacts with the α:σ2 hemicomplex, but does not interact with the assembled AP2 heterotetramer (<xref ref-type="bibr" rid="c66">Wan et al., 2024</xref>). To explore this apparent discrepancy, we conducted co-immunoprecipitation (co-IP) experiments from cell lysates of ARPE-HPV cells that stably express a fully functional eGFP-tagged α-subunit of AP2 (<xref ref-type="bibr" rid="c46">Mino et al., 2020</xref>) (AP2-α-eGFP, <xref rid="fig5" ref-type="fig">Fig. 5B</xref>). Mass Spectrometry analysis revealed, as expected, the co-IP of all the subunits of the AP2 complex, as well as well-known AP2 binding proteins (i.e. EPS15, NECAP2, AAK1 and AAGAB) (<xref ref-type="bibr" rid="c44">Mettlen et al., 2018</xref>). Notably, CCDC32 was also efficiently co-immunoprecipitated with intact AP2 (<xref rid="fig5" ref-type="fig">Fig. 5C</xref>; <xref ref-type="table" rid="tbls1">Table S1</xref>). However, this experiment does not definitively rule out the possibility that CCDC32 only interacts with a small population of immature α:σ2 hemicomplexes that might be present in the lysate. Therefore, we performed co-IP experiments in cell lysates from ARPE-HPV cells stably expressing eGFP-CCDC32(FL) (<xref rid="fig5" ref-type="fig">Fig. 5D</xref>). Western blotting showed that the α subunit (<xref rid="fig5" ref-type="fig">Fig. 5E-F</xref>), together with each of AP2 complex subunits (<xref ref-type="fig" rid="figs3">Fig. S3C</xref>) were efficiently co-precipitated with eGFP-CCDC32(FL), but not by GFP (<xref rid="fig5" ref-type="fig">Fig. 5D-F</xref>). Thus, we conclude that CCDC32 interacts with the mature AP2 complex. The discrepancy with previous findings may be due to the location of the eGFP tag (see discussion).</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5:</label>
    <caption><title>CCDC32 interacts with AP2 through the α appendage domain.</title><p>(A) AP2 structure. AD: appendage domain. <bold>(B)</bold> Domain structure of a fully-functional α-subunit bearing an internal eGFP tag inserted in the unstructured hinge region. <bold>(C)</bold> Volcano plot after mass spectrometry analysis of the immunoprecipitation (IP) of eGFP from naive ARPE-HPV cells (control IPs) or ARPE-HPV cells that stably express AP2-α-eGFP (AP2-α-eGFP IPs) using anti-GFP beads. Green: AP2 subunits; orange: known AP2 interactors. Source data for the volcano plot is available as <xref ref-type="table" rid="tbls2">Table S2</xref>. <bold>(D-F)</bold> IP of eGFP from ARPE-HPV cells that stably express eGFP or eGFP-CCDC32(FL) using anti-GFP magnetic beads. (D) The domain structures of eGFP and eGFP-CCDC32(FL). (E) Representative immunoblotting result of n=3 IP samples. (F) Relative AP2 enrichments quantified from immunoblotting results. <bold>(G-I)</bold> GST pull-down assays. (G) Quantification of immunoblots of the relative enrichment of CCDC32. (H) Coomassie blue stained SDS-page gel of purified GST, GST-AP2-α-AD, and GST-AP2-β-AD. (I) Representative western blot result of n=3 GST pull-down assay from ARPE-HPV eGFP-CCDC32(FL) cell lysate using purified GST, GST-AP2-α-AD, or GST-AP2-β-AD. The amount of bait GST-proteins is shown in (D), and the pulled down eGFP-CCDC32 was detected by immunoblotting (IB) of GFP. Error bars in (F) and (I) are SD (n=3).Two-tailed student’s t-test: ***, p ≤ 0.001.</p></caption>
<graphic xlink:href="600785v4_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Most endocytic accessory proteins interact with AP2 via the appendage domains of the α and β2 subunits (<xref ref-type="bibr" rid="c48">Praefcke et al., 2004</xref>; <xref ref-type="bibr" rid="c51">Schmid et al., 2006</xref>) (<xref rid="fig5" ref-type="fig">Fig. 5A</xref>, α-AD and β-AD). Therefore, we expressed and purified GST-tagged AP2 α-AD and β-AD (<xref rid="fig5" ref-type="fig">Fig. 5G</xref>) and used GST pull-down assays to test which might interact with CCDC32. GST-AP2-α-AD, but not GST-AP2-β-AD, was capable of pulling down CCDC32 from ARPE-HPV eGFP-CCDC32(FL) cell lysate (<xref rid="fig5" ref-type="fig">Fig. 5H,I</xref>). Thus, CCDC32 can interact with AP2 via the α-AD.</p>
</sec>
<sec id="s2e">
<title>Identification of a CCDC32 binding site for AP2 interactions</title>
    <p>We next identified a region on CCDC32 responsible for AP2 binding. Structural predictions of CCDC32 made by AlphaFold 3.0 show it to be a mainly unstructured protein with several isolated α-helices (<xref ref-type="fig" rid="figs6">Fig. S6A,B</xref>), which likely led to its misnomer as a coiled-coil domain containing protein. Indeed, even when modelled as a dimer or trimer, we found no evidence of coiled-coil interactions between the α-helices (data not shown). Moreover, endogenous CCDC32 did not co-immuno-precipitate with eGFP-CCDC32 from ARPE-HPV eGFP-CCDC32(FL) cell lysate (<xref ref-type="fig" rid="figs6">Fig. S6C</xref>), indicating that the protein is a monomer <italic>in vivo</italic>. Nonetheless, we focused first on a strongly predicted α-helix encoded by aa78-98 and located in the middle of CCDC32 and engineered a CCDC32 construct lacking this α-helix (Δ78-98, <xref rid="fig6" ref-type="fig">Fig. 6A</xref>; <xref ref-type="fig" rid="figs6">Fig. S6A-B</xref>). The corresponding siRNA-resistant CCDC32(Δ78-98) mutant was stably expressed in ARPE-HPV cells at comparable expression levels to eGFP-CCDC32(FL) (<xref ref-type="fig" rid="figs1">Fig. S1A</xref>). As previously showed (<xref ref-type="fig" rid="figs3">Fig. S3C</xref>) all four subunits of AP2 efficiently co-IP with full length CCDC32 from cell lysates (<xref rid="fig6" ref-type="fig">Fig. 6B,C</xref>). Interestingly, the co-IPs of both α and σ2 subunits with CCDC32(Δ78-98) were greatly reduced (<xref rid="fig6" ref-type="fig">Fig. 6B,C</xref>); whereas, unexpectedly the ability of CCDC32(Δ78-98) to interact with β2:µ2 was unaffected. These data are partially consistent with the results of Wan et al.(<xref ref-type="bibr" rid="c66">Wan et al., 2024</xref>), who reported interactions with the α:σ2 hemicomplex and with µ2, but not with β2. Given the efficiency and selectivity of our co-IP, our data also suggests that the mature AP2 complex exists in a dynamic equilibrium between α:σ2 and β2:µ2 hemicomplexes. . Indeed, it has previously been reported that β2:µ2 hemicomplexes can partially support synaptic vesicle recycling in C. elegans bearing null mutations in the α-subunit of AP2(<xref ref-type="bibr" rid="c22">Gu et al., 2013</xref>). These findings demonstrate that aa78-98 are essential for CCDC32 interactions with both mature AP2 complexes and the α:σ2 hemicomplex.</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6:</label>
<caption><title>A central α-helix in CCDC32 mediates CCDC32-AP2 interactions.</title><p>(A-C) IP of eGFP from ARPE-HPV cells that stably express eGFP-CCDC32(FL) or eGFP-CCDC32(Δ78-98) using anti-GFP beads. (A) The domain structures of eGFP-CCDC32(FL) and eGFP-CCDC32(Δ78-98). (B) Representative Immunoblotting result of n=3 IP samples. (C) Relative AP2 enrichments that were quantified from (B). Error bars indicate standard deviations. <bold>(D)</bold> Representative TIRFM images of ARPE-HPV cells that stably express mRuby-CLCa and eGFP-CCDC32(Δ78-98). White ROI is magnified on the right. Scale bar = 5µm. <bold>(E)</bold> Cohort-averaged fluorescence intensity traces of CCPs and CCP-enriched eGFP-CCDC32(Δ78-98). Number of tracks analyzed: 37892. <bold>(F-G)</bold> (F) TfnR uptake efficiency and (G) CCP% of ARPE mRb-CLCa cells that stably express eGFP-CCDC32(WT), eGFP, or eGFP-CCDC32(Δ78-98), and with siRNA-mediated knockdown of endogenous CCDC32. Each dot in (G) represents a movie. Statistical analysis of the data in (F) is two-tailed student’s t-test: ns, not significant; ***, p ≤ 0.001. Statistical analysis of the data in (G) is the Wilcoxon rank sum test, **, p ≤ 0.01.</p></caption>
<graphic xlink:href="600785v4_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Disrupting AP2 interactions severely impaired the recruitment of CCDC32(Δ78-98) to CCPs (<xref rid="fig6" ref-type="fig">Fig. 6D,E</xref>), indicating that CCDC32 is likely recruited to CCPs through its interactions with AP2. Notably, unlike CCDC32(FL), CCDC32(Δ78-98) was unable to rescue either the uptake of the CME cargo, TfnR (<xref rid="fig6" ref-type="fig">Fig. 6F</xref>) or the stabilization of CCPs (<xref rid="fig6" ref-type="fig">Fig. 6G</xref>). Together, these results establish that CCDC32, a previously uncharacterized endocytic accessory protein, plays a critical role in regulating CCP stabilization and invagination.</p>
</sec>
<sec id="s2f">
<title>Disease-causing nonsense mutation in CCDC32 loses AP2 interaction capacity and inhibits CME</title>
    <p>Loss-of-function nonsense mutations in CCDC32 have been reported to result in CFNDS (<xref ref-type="bibr" rid="c1">Abdalla et al., 2022</xref>; <xref ref-type="bibr" rid="c24">Harel et al., 2020</xref>); however, the disease-causing mechanism remains unknown. The identified frameshift mutations result in premature termination and truncation of the protein at residue 10, 55 or 81 (<xref ref-type="bibr" rid="c24">Harel et al., 2020</xref>). Based on our findings, we hypothesize that these C-terminally truncated mutants, all of which lack the α-helix encoded by residues 78-98, will be defective in AP2 binding and unable to function in CME. To test this hypothesis, we generated an siRNA-resistant eGFP-CCDC32(1-54) construct (<xref rid="fig7" ref-type="fig">Fig. 7A</xref>) based on the clinical report (<xref ref-type="bibr" rid="c24">Harel et al., 2020</xref>), and stably expressed this truncated CCDC32 mutant in ARPE-HPV cells (<xref ref-type="fig" rid="figs1">Fig. S1A</xref>).</p>
<fig id="fig7" position="float" orientation="portrait" fig-type="figure">
<label>Figure 7:</label>
<caption><title>Disease-causing nonsense mutation in CCDC32 loses AP2 interaction capacity and inhibits CME.</title><p>(A-C) IP of eGFP from ARPE-HPV cells that stably express eGFP-CCDC32(FL) or eGFP-CCDC32(1-54) using anti-GFP magnetic beads. (A) The domain structures of eGFP-CCDC32(FL) and eGFP-CCDC32(1-54). (B) Representative immunoblotting result of n=3 IP samples. (C) Relative AP2 enrichments quantified from immunoblotting results. <bold>(D)</bold> Representative TIRFM images of ARPE-HPV cells that stably express mRuby-CLCa and eGFP-CCDC32(1-54). White ROI is magnified on the right. Scale bar = 5µm. <bold>(E)</bold> Cohort-averaged fluorescence intensity traces of CCPs and CCP-enriched eGFP-CCDC32(1-54). Number of tracks analyzed: 28658. <bold>(F-G)</bold> (F) TfnR uptake efficiency and (G) CCP% of ARPE-HPV cells that stably express eGFP-CCDC32(FL), eGFP, or eGFP-CCDC32(1-54), and with siRNA-mediated knockdown of endogenous CCDC32. Each dot in (G) represents a movie. Statistical analysis of the data in (F) is two-tailed student’s t-test: ***, p ≤ 0.001. Statistical analysis of the data in (G) is the Wilcoxon rank sum test, **, p ≤ 0.01.</p></caption>
<graphic xlink:href="600785v4_fig7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
    <p>As predicted, AP2 did not co-IP with CCDC32(1-54) from the cell lysate (<xref rid="fig7" ref-type="fig">Fig. 7B,C</xref>), confirming that the disease-causing mutation in CCDC32 abolishes its interactions with AP2. Correspondingly, we could not detect CCDC32(1-54) recruitment to CCPs in dual channel TIRFM imaging (<xref rid="fig7" ref-type="fig">Fig. 7D,E</xref>), consistent with CCP recruitment of CCDC32 being dependent on CCDC32-AP2 interactions. Interestingly, we also noticed that the level of diffuse plasma membrane binding detected by TIRFM decreased to a greater extent than that seen for CCDC32(Δ78-98), now corresponding to background, eGFP only levels (see <xref ref-type="fig" rid="figs7">Fig. S7</xref> for direct comparison). These data suggest that the C-terminus of CCDC32 is required for binding to the inner surface of the plasma membrane. Finally, we observed that expression of eGFP-CCDC32(1-54), after siRNA-mediated knockdown of endogenous CCDC32, was unable to rescue TfnR uptake efficiency (<xref rid="fig7" ref-type="fig">Fig. 7F</xref>) or CCP stabilization (<xref rid="fig7" ref-type="fig">Fig. 7G</xref>). These findings show that this loss-of-function nonsense mutation in CCDC32 abolishes its interactions with AP2 and inhibits CME likely contributing to the development of CFNDS.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>CCDC32 was identified through genetic studies, originally in a yeast 2-hybrid screen for proteins interacting with annexin A2 (<xref ref-type="bibr" rid="c35">Li et al., 2011</xref>) and subsequently via whole exome sequencing to identify mutations associated with cranio-facio-neurodevelopmental syndrome (CFNDS) (<xref ref-type="bibr" rid="c1">Abdalla et al., 2022</xref>; <xref ref-type="bibr" rid="c24">Harel et al., 2020</xref>), neither of which provided insight into its cellular function. Subsequent bioinformatic analysis of co-essential modules linked CCDC32 with the AP2 adaptor complex, provided evidence for its interaction with AP2, reported colocalization of CCDC32 with AP2 at CCPs, and demonstrated a role in CME (<xref ref-type="bibr" rid="c65">Wainberg et al., 2021</xref>). A more recent report has suggested that CCDC32 functions as a chaperone, essential for the assembly of mature AP2 heterotetrametric complexes (<xref ref-type="bibr" rid="c66">Wan et al., 2024</xref>), but that CCDC32 neither binds to the mature AP2 complex nor colocalizes with CCPs.</p>
<p>Here we show that CCDC32 binds to intact AP2 complexes and that this interaction is required for its recruitment to CCPs. Our data demonstrate that CCDC32 plays a critical role at early stages of CME, dependent on its recruitment to CCPs. Depletion of CCDC32 results in a pronounced defect in CCP invagination, a decrease in the rate of formation and percentage of stabilized nascent <italic>bona fide</italic> CCPs and an accumulation of flat clathrin assemblies, unstable intermediates in CCP formation (<xref rid="fig8" ref-type="fig">Fig. 8</xref>). Despite these profound alterations in CCP dynamics, CME itself, as measured by TfnR internalization efficiency, is only partially inhibited. We speculate that this mild endocytic defect reflects the plasticity and resilience of CME. Indeed, we detect two potential compensatory mechanisms that occur upon depletion of CCDC32, namely an increase in the rate of CCS assembly and a decrease in the lifetimes of dynamic <italic>bona fide</italic> CCPs (i.e. an increased rate of CCP maturation) (<xref rid="fig8" ref-type="fig">Fig. 8</xref>).</p>
<fig id="fig8" position="float" orientation="portrait" fig-type="figure">
<label>Figure 8:</label>
    <caption><title>Cartoon illustration of CCDC32-AP2 interactions that regulate CME.</title>
        <p>Interactions between residues 78-98, corresponding to a central α-helix of CCDC32, and AP2 are essential for recruitment of CCDC32 to CCPs. Depleting CCDC32 (ΔCCDC32) inhibits CCP stabilization and invagination, resulting in enhanced CCS abortion and accumulated flat clathrin assembly intermediates. As a compensation effect, CCS initiation is enhanced and CCP maturation is faster, resulting in only slightly reduced cargo internalization. EAPs: endocytic accessory proteins.</p></caption>
<graphic xlink:href="600785v4_fig8.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>While individual depletion of other endocytic accessory proteins has been reported to result in one or more of these phenotypes, to our knowledge, this combination of phenotypes has not been detected. Instead, either CCP assembly is reduced (<xref ref-type="bibr" rid="c26">Henne et al., 2010</xref>; <xref ref-type="bibr" rid="c62">Umasankar et al., 2014</xref>) or CCPs accumulate at later stages of invagination (<xref ref-type="bibr" rid="c40">McMahon and Boucrot, 2011</xref>; <xref ref-type="bibr" rid="c43">Messa et al., 2014</xref>). This combination of phenotypes has, however, been observed previously in cells expressing a truncated mutant of AP2 lacking the α-AD (<xref ref-type="bibr" rid="c3">Aguet et al., 2013</xref>). These cells also exhibited: i) near normal Tfn uptake, ii) an accumulation of flat clathrin assemblies, which are rapidly turned over, iii) an increase in the rate of nascent CCS initiation, iv) impaired stabilization of dynamic CCPs and, v) a decrease in productive CCP lifetimes. We speculate that loss of CCDC32 recruitment could have accounted for these unique phenotypes.</p>
    <p>Although the mechanism of CCP invagination has been an important topic for decades, which endocytic accessory proteins (if any) regulate CCP invagination and (if so) how, has remained unclear. The depletion of CCDC32 in cells strongly inhibited the formation of dome-shaped and spherical CCSs, and instead resulted in the accumulation of flat clathrin assemblies. As the area of these clathrin lattices was insufficient to form a complete CCV, they likely represent defective CCP assembly intermediates that are rapidly turned over as abortive CCPs. This experimentally observed requirement of CCDC32 in CCP invagination is consistent with previous findings that clathrin assembly alone was not sufficient to induce CCP invagination in cells (<xref ref-type="bibr" rid="c3">Aguet et al., 2013</xref>), potentially due to the reported flexibility of clathrin coats (<xref ref-type="bibr" rid="c17">Ferguson et al., 2008</xref>; <xref ref-type="bibr" rid="c59">Tagiltsev et al., 2021</xref>). The mechanism by which CCDC32 promotes CCP invagination remains to be determined, but other domains of the protein may bind to and stabilize the clathrin coat, or the predicted largely disordered structure of CCDC32 (<xref ref-type="fig" rid="figs6">Fig. S6</xref>) may generate membrane curvature by molecular crowding (<xref ref-type="bibr" rid="c8">Busch et al., 2015</xref>).</p>
    <p>We localized the AP2 binding site on CCDC32, which is essential for CCDC32-AP2 interactions <italic>in vivo</italic>, to a short, predicted alpha-helical region (aa78-98). Interestingly, this sequence, LASLEKKLRRIKGLNQEVTSKD, does not encode any of the known AP2 α-AD binding motifs (e.g. DxF/W, FxDxF, WxxF/W, FxxFxxL) commonly shared amongst other AP2 interacting partners (<xref ref-type="bibr" rid="c47">Olesen et al., 2008</xref>). However, we identified two canonical α-AD binding motifs in CCDC32 (<sup>17</sup>DLW<sup>19</sup> and <sup>39</sup>FSDSF<sup>43</sup>), both of which can be docked on the AP2 appendage domain with high confidence using AlphaFold 3.0 (<xref ref-type="fig" rid="figs6">Fig. S6D,E</xref>). While these binding motifs may have been sufficient for <italic>in vitro</italic> interactions with α-AD, they were not sufficient for AP2 binding <italic>in vivo</italic>. Unexpectedly, AlphaFold 3.0 modeling predicts, with high confidence, that the α-helical region we identified as essential for AP2 binding <italic>in vivo</italic> docks to an alpha helix formed by aa418-436 of the α-subunit (<xref ref-type="fig" rid="figs6">Fig. S6D,F</xref>), which is not encoded in our α-AD construct. This site is located in the α-trunk and buried with the AP2 core domain (<xref ref-type="bibr" rid="c12">Collins et al., 2002</xref>). However, it becomes accessible when the C-terminal domain of µ2 adopts the open conformation triggered by cargo binding (<xref ref-type="bibr" rid="c27">Jackson et al., 2010</xref>). Thus, we speculate that CCDC32 may preferentially interact with membrane-bound AP2. Interestingly, while co-IP with CCDC32(Δ78-99) no longer pulled down the intact AP2 complex or the α:σ2 hemicomplex, it remained capable of pulling down the β2:µ2 hemicomplex. This result has a number of interesting implications: first that the extended full length CCDC32 has multiple points of interaction with AP2 and its subunits, that will require further studies to structurally and functionally define; and second, that the AP2 complex is less stable than previously assumed (i.e. the 2 hemicomplexes must be in flux). Indeed, it has been shown that β2:µ2 hemicomplexes can partially support synaptic vesicle recycling in C. elegans bearing null mutations of the α-subunit (<xref ref-type="bibr" rid="c22">Gu et al., 2013</xref>).Further structural studies will be needed to identify the full extent of CCDC32 interactions with the AP2 complex.</p>
<p>While this paper was under review, it was reported that CCDC32 functions together with AAGAB, as an essential chaperone for AP2 assembly (<xref ref-type="bibr" rid="c66">Wan et al., 2024</xref>). While there are discrepancies, our results are not incompatible with their findings. Thus, it is possible, even likely, that the ∼40% residual CCDC32 present after siRNA knockdown may be sufficient to fulfill its catalytic chaperone activity in facilitating AP2 complex assembly, but not its presumed structural role in regulating early stages of CME. The inability of Wan et al. to detect CCDC32 binding to mature AP2 complexes or β2:µ2 hemicomplexes or its recruitment to CCPs may reflect a perturbed function of the C-terminally tagged construct (<xref ref-type="bibr" rid="c66">Wan et al., 2024</xref>). Indeed, their images show the formation of large (&gt;100 nm), cytoplasmic puncta of CCDC32-GFP, which might be reflective of protein aggregation. Moreover, our data show a role for the C-terminus in diffuse plasma membrane binding. Finally, we find that the Δ78-98 mutant retains its ability to bind the β2:µ2 hemicomplex, but loses its ability to bind α:σ2 hemicomplex. Thus, the most parsimonious conclusion is that CCDC32 is multifunctional, acting catalytically to facilitate AP2 assembly and, after recruitment to CCPs, to regulate early stages of CME. Further studies are needed to fully elucidate the mechanisms governing each of these functions.</p>
<p>Our results provide an explanation for how the clinically observed loss-of-function mutations in CCDC32 result in the development of CFNDS. As we have shown, the disease-associated CCDC32 loss-of-function mutants are not capable of interacting with intact AP2, thus losing their AP2 regulation capacity. Our results suggest that the inability to bind mature AP2 and hence to be recruited to nascent CCSs inhibits critical early stages of CME, and contributes to the development of CFNDS. While we cannot rule of nonsense-mediated decay and resulting loss of expression of the truncated human mutations (<xref ref-type="bibr" rid="c38">Lykke-Andersen and Jensen, 2015</xref>), it is interesting that the clinical features of CCDC32 loss-of-function are similar to those resulting from AP2 loss-of-function mutations (<xref ref-type="bibr" rid="c4">Arrigo and Lin, 2021</xref>; <xref ref-type="bibr" rid="c20">Gorvin et al., 2017</xref>; <xref ref-type="bibr" rid="c25">Helbig et al., 2019</xref>; <xref ref-type="bibr" rid="c30">Jung et al., 2015</xref>; <xref ref-type="bibr" rid="c34">Li et al., 2018</xref>; <xref ref-type="bibr" rid="c36">Li et al., 2010</xref>), supporting that CCDC32 functions through AP2. However, we suggest that the disease-associated CFNDS mutants are hypomorphic, as the complete loss of AP2 complexes, which would result from a complete loss of the CCDC32 protein (<xref ref-type="bibr" rid="c66">Wan et al., 2024</xref>), has been shown to be embryonic lethal in Drosophila (<xref ref-type="bibr" rid="c19">González-Gaitán and Jäckle, 1997</xref>) and zebrafish (<xref ref-type="bibr" rid="c63">Umasankar et al., 2012</xref>).</p>
<p>In summary, our study identified CCDC32 as an important endocytic accessory protein that regulates CCP stabilization and invagination via its interactions with AP2. Future work needs to address the multifunctional interactions of CCDC32 with AP2 and to define exactly how CCDC32 enhances curvature generation and coat stabilization.</p>
</sec>
<sec id="s4">
<title>Materials and Methods</title>
<sec id="s4a">
<title>Plasmids</title>
    <p>The eGFP-CCDC32(FL, human) cDNA in a pEGFP-C1 vector was purchased from Addgene (#110505) and then mutated to be siRNA resistant, which retained amino acid sequence (#98-102) while modifying the nucleotide sequence. Next, aa78-98 was deleted from siRNA resistant eGFP-CCDC32(FL) to generate eGFP-CCDC32(Δ78-98). Finally, eGFP, eGFP-CCDC32(1-54), eGFP-CCDC32(Δ78-98), and eGFP-CCDC32(FL) were separately cloned into a pLVx-CMV100 vector (<xref ref-type="bibr" rid="c14">Dean et al., 2016</xref>) using NEBuilder® HiFi DNA Assembly Master Mix (Catalog #E2621). A full list of primers used for mutagenesis and cloning is available in <xref ref-type="table" rid="tbls2">Table S2</xref>. Note that our disease mimic construct CCDC32(1-54) does not contain a 9 aa peptide (VRGSCLRFQ) in the N-terminus and an extra 12 aa in the C-terminus when CFNDS patient mutation was described (p.(Glu64Glyfs∗12)) in ref. (<xref ref-type="bibr" rid="c24">Harel et al., 2020</xref>).</p>
<p>In addition, mRuby-CLCa in a pLVx-IRES-puro vector was generated in our previous study(<xref ref-type="bibr" rid="c56">Srinivasan et al., 2018</xref>). AP2-α-AD (aa701-938, mouse) in a pGEX-2T-1 vector and AP2-β-AD (aa592-937, rat) in a pGEX-4T-1 vector were kind gifts of the late Linton Traub (University of Pittsburgh, PA).</p>
</sec>
<sec id="s4b">
<title>Cell culture, lentivirus infection, siRNA transfection and rescue</title>
<p>ARPE-19 and ARPE19-HPV16 (herein called ARPE-HPV) cells were obtained from ATCC and cultured in DMEM/F12 (Gibco, Catalog #8122502) with 10% FBS. HEK293T cells were obtained from ATCC and cultured in DMEM (Gibco, Catalog #8122070) with 10% FBS. ARPE-HPV cells that stably express eGFP-CLCa were generated in our previous study (<xref ref-type="bibr" rid="c9">Chen et al., 2020</xref>). ARPE-HPV cells that stably express a fully functional AP2-α-eGFP, in which eGFP is inserted into the flexible linker of AP2, at aa649, were generated in our previous study (<xref ref-type="bibr" rid="c46">Mino et al., 2020</xref>) and this AP2-α-eGFP construct has been shown to be fully functional.</p>
<p>Lentiviruses encoding mRuby-CLCa were produced in HEK293T packaging cells following standard transfection protocols (<xref ref-type="bibr" rid="c33">Kutner et al., 2009</xref>) and harvested for subsequent infections to ARPE-HPV cells to generate ARPE-HPV mRuby-CLCa cells. Lentiviruses encoding eGFP and siRNA-resistant, eGFP-CCDC32(1-54), eGFP-CCDC32(Δ78-98), and eGFP-CCDC32(FL) were produced in HEK293T packaging cells and harvested for subsequent infections to ARPE-HPV mRuby-CLCa cells. Infected cells were FACS sorted for homogenous mRuby and eGFP signals after 3 days and passaged for 2 weeks before experiments.</p>
<p>For siRNA-mediated knockdown of CCDC32, ARPE-HPV cells stably expressing eGFP-CLCa were seeded on 6-well plates (250,000 cells/well) and transfected with 2 rounds of siCCDC32 (Silencer Select Pre-designed siRNA ID#: s228444, targets aa98-102 sequence) through 3 days. Cells treated with siControl (Silencer Select Negative Control #1 siRNA, cat#:4390843) were used as negative control. Transfections of siRNA were mediated with Opti-MEM and Lipofectamine RNAi-MAX (Invitrogen) as detailed in ref. (<xref ref-type="bibr" rid="c9">Chen et al., 2020</xref>).</p>
<p>For CCDC32 rescue experiments, ARPE-HPV cells stabily expressing eGFP or siRNA-resistant eGFP-CCDC32(FL) eGFP, eGFP-CCDC32(Δ78-98 or eGFP-CCDC32(1-54) were transfected with siCCDC32 or siControl as described above. Anti-GFP Monoclonal Antibody (Proteintech, # 66002-1-Ig), Anti-Vinculin Polyclonal Antibody (Proteintech, #26520-1-AP), and anti-C15orf57 Polyclonal antibody (Invitrogen, #PA5-98982) were used in Western Blotting to confirm protein expression level and knockdown efficiency.</p>
</sec>
<sec id="s4c">
<title>Co-immunoprecipitation (co-IP)</title>
<p>ARPE-HPV cells with stable expression of AP2-α-eGFP, eGFP, eGFP-CCDC32(1-54), eGFP-CCDC32(Δ78-98) or eGFP-CCDC32(FL) were cultured in a 15-cm dish. When confluence reached ∼90%, cells were washed 3x with ice-cold PBS and detached with cell scratcher. Next, cells were spun down at 500 g, 4°C for 3 min, and then resuspended in 1ml ice-cold lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1mM EDTA, 0.5% Triton X-100, 1× protease inhibitor, 1mM PMSF). After 30 min rotation in a cold room and occasional vortexing, the lysed cells were spun at 500 g, 4°C, for 3 min to remove the nuclei. Subsequently, 50µl anti-GFP magnetic beads (Biolinkedin, #L1016) were added to cell lysate that contained 0.5mg proteins (determined by BCA assay). The reaction was allowed to proceed by rotation at 4°C for 2h and then precipitated with DynaMag. The sediments were washed with lysis buffer, and then resuspended and heat-denatured in 2x Laemmli buffer (supplemented with 5% β-Mercaptoethanol). The final samples were run into SDS-PAGE gels before: 1) being transferred to membranes for Western Blotting; or 2) being sent to the proteomics core facility for mass spectrometry analysis. Anti-α-Adaptin 1/2 Antibody (C-8) (Santa Cruz Biotechnology,</p>
<p>Catalog #sc-17771) was used in WB to detect AP2 enrichments.</p>
</sec>
<sec id="s4d">
<title>Mass Spectrometry Analysis</title>
<p>Samples were digested overnight with trypsin (Pierce) following reduction and alkylation with DTT and iodoacetamide (Sigma–Aldrich). Following solid-phase extraction cleanup with an Oasis HLB µelution plate (Waters), the resulting peptides were reconstituted in 10 µL of 2% (v/v) acetonitrile (ACN) and 0.1% trifluoroacetic acid in water. 2 µL of each sample were injected onto an Orbitrap Fusion Lumos mass spectrometer (Thermo Electron) coupled to an Ultimate 3000 RSLC-Nano liquid chromatography systems (Dionex). Samples were injected onto a 75 μm i.d., 75-cm long EasySpray column (Thermo), and eluted with a gradient from 0-28% buffer B over 90 min. Buffer A contained 2% (v/v) ACN and 0.1% formic acid in water, and buffer B contained 80% (v/v) ACN, 10% (v/v) trifluoroethanol, and 0.1% formic acid in water. The mass spectrometer operated in positive ion mode with a source voltage of 2.4 kV and an ion transfer tube temperature of 275 °C. MS scans were acquired at 120,000 resolution in the Orbitrap and up to 10 MS/MS spectra were obtained in the Orbitrap for each full spectrum acquired using higher-energy collisional dissociation (HCD) for ions with charges 2-7. Dynamic exclusion was set for 25 s after an ion was selected for fragmentation.</p>
<p>Raw MS data files were analyzed using Proteome Discoverer v2.4 (Thermo), with peptide identification performed using Sequest HT searching against the human reviewed protein database from UniProt. Fragment and precursor tolerances of 10 ppm and 0.6 Da were specified, and three missed cleavages were allowed. Carbamidomethylation of Cys was set as a fixed modification and oxidation of Met was set as a variable modification. The false-discovery rate (FDR) cutoff was 1% for all peptides. To generate the volcano plot, Tubulin Beta 6 was used for Normalization.</p>
<p>The data was uploaded to the MassIVE data repository with accession number MSV000095338.</p>
</sec>
<sec id="s4e">
<title>Protein purification and GST pull-down assay</title>
<p>GST in a pGEX-6P-1 vector, GST-AP2-α-AD in a pGEX-2T-1 vector, and GST-AP2-β-AD in a pGEX-4T-1 vector were transfected and expressed in BL21(DE3) separately, and then affinity purified using GSTrap HP column (Cytiva). The affinity-purified GST fusion proteins were applied to a HiLoad 16/600 Superdex 200 pg column (Cytiva). Target proteins were collected and concentrated using Amicon Ultra-15 10K Centrifugal filters (Sigma-Aldrich), and stored in 20 mM HEPES, 150 mM NaCl, 1mM TCEP, pH 7.4.</p>
<p>In GST pull-down assays, purified GST, GST-AP2-α-AD, and GST-AP2-β-AD were pre-bound to anti-GST beads (Biolinkedin, #L-2004). Subsequently, these beads were separately added into 0.5 mg cell lysate of ARPE-HPV eGFP-CCDC32(FL). The reactions were allowed to proceed by rotation at 4°C for 2h, and then the beads were spun down at 1000 g, 4°C for 3 min. The sediments were washed with lysis buffer, and then heat-denatured in 2x Laemmli buffer (supplemented with 5% β-Mercaptoethanol) before running into SDS-PAGE gels, which followed by Western Blotting analysis.</p>
</sec>
<sec id="s4f">
<title>Transferrin receptor (TfnR) uptake assay</title>
<p>Internalization of TfnR was quantified by in cell ELISA following established protocols described (<xref ref-type="bibr" rid="c9">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="c13">Conner and Schmid, 2003</xref>; <xref ref-type="bibr" rid="c49">Reis et al., 2015</xref>; <xref ref-type="bibr" rid="c55">Srinivasan et al., 2018</xref>). Briefly, ∼15,000 cells were seeded on gelatin-coated 96-well plate overnight. Next day, cells were starved in 37°C-warm PBS<sup>4+</sup> (1× PBS buffer plus 0.2% BSA, 1mM CaCl<sub>2</sub>, 1mM MgCl<sub>2</sub>, and 5mM D-glucose) for 30 min. After starvation, the cell medium was replaced with ice-cold PBS<sup>4+</sup> containing 5 µg/ml HTR-D65 (anti-TfnR mAb) (<xref ref-type="bibr" rid="c52">Schmid and Smythe, 1991</xref>). In parallel, some cells were kept at 4°C for the measurement cell surface TfnR (denoted as S) and blank controls (denoted as B), while some were incubated in a 37°C water bath for the indicated times for the measurement of internalized TfnR (denoted as I). For B and I, acid wash (0.2 M acetic acid and 0.2 M NaCl, pH 2.3) was applied to remove surface-bound HTR-D65. After washing with cold PBS. All cells were fixed with 4% PFA (Electron Microscopy Sciences) diluted in PBS for 30 min at 37°C. Subsequently, the cells were permeabilized with 0.1% Triton X-100 and blocked with Q-PBS (PBS, 2% BSA, 0.1% lysine, and 0.01% saponin, pH 7.4) for 2h. Surface-bound and internalized HTR-D65 were detected with HRP Goat anti-Mouse IgG (H+L) (BioRad) and o-phenylenediamine dihydrochloride (OPD, Sigma-Aldrich). Well-to-well variation of cell numbers was accounted for by BCA assays.</p>
</sec>
<sec id="s4g">
<title>TIRF and Epi-TIRF microscopy</title>
<p>Cells for imaging were seeded on gelatin-coated glass bottom dishes 35 mm (ibidi, #81218-800) for ∼12h before data acquisition. Live cell imaging was conducted with a Nikon Eclipse Ti2 inverted microscope that was equipped with: 1) an Apo TIRF/100x 1.49 Oil objective; 2) a Prime Back Illuminated sCMOS Camera (Prime BSI, 6.5 x 6.5µm pixel size and 95% peak quantum efficiency; 3) a M-TIRF module for epifluorescence (Epi) acquisition; 4) an H-TIRF module for TIRF acquisition, where penetration depth was fixed to 80nm; 5) an Okolab Cage Incubator for maintaining 37°C and 5% CO<sub>2</sub>.</p>
<p>For time-lapse TIRF imaging, 451 consecutive images were acquired at a frame rate of 1 frame/s for single channel or 0.5 frame/s for dual channels. For time-lapse Epi-TIRF imaging, 451 consecutive Epi and TIRF images were acquired nearly simultaneously at a frame rate of 0.66 frame/s. Perfect Focus System (PFS) was applied during time-lapse imaging.</p>
<p>The acquired data was analyzed using cmeAnalysis (<xref ref-type="bibr" rid="c3">Aguet et al., 2013</xref>; <xref ref-type="bibr" rid="c28">Jaqaman et al., 2008</xref>) and DASC (<xref ref-type="bibr" rid="c67">Wang et al., 2020</xref>), which are available at: <ext-link ext-link-type="uri" xlink:href="https://github.com/DanuserLab/cmeAnalysis">https://github.com/DanuserLab/cmeAnalysis</ext-link>. Detailed protocols are available via this link. Briefly, cmeAnalysis was used to track the lifetime and fluorescence of clathrin-coated structures, and then DASC was applied to unbiasedly classify <italic>bona fide</italic> CCPs vs. abortive coats. Next, the classified CCP tracks were used to calculate CCP invagination (Δz), as previously described (<xref ref-type="bibr" rid="c67">Wang et al., 2020</xref>). Tracks that overlap with others or deviate from the properties of a diffraction-limited particle were excluded from the analysis.</p>
</sec>
<sec id="s4h">
<title>Platinum Replica Electron Microscopy (PREM)</title>
<p>The “unroofing” technique that mechanically removes the upper cell plasma membrane while preserving the ventral plasma membrane with CCSs and other structures for PREM analyses was performed essentially as described previously (<xref ref-type="bibr" rid="c69">Yang et al., 2022</xref>). Briefly, ARPE19 cells treated with siCCDC32 or siControl on coverslips were quickly transferred into ice-cold PEM buffer (100LmM PIPES−KOH, pH 6.9, 1LmM MgCl2 and 1LmM EGTA) containing 2LµM unlabeled phalloidin (Sigma , #P2141) and 10LµM taxol (Sigma-Aldrich, #T7402) and unroofed by a brief (1s) ultrasonic burst from a 1/8-inch microprobe positioned at ∼45° angle ∼3 mm above the coverslip and operated by Misonix XL2020 Ultrasonic Processor at 17-20% of output power. After sonication, the coverslips were immediately fixed with 2% glutaraldehyde in 0.1 M Na-cacodylate buffer, pH 7.3 for at least 20 min at room temperature.</p>
<p>Sample processing for PREM was performed as described previously (<xref ref-type="bibr" rid="c56">Svitkina, 2022</xref>). In brief, glutaraldehyde-fixed cells were post-fixed by sequential treatment with 0.1% tannic acid and 0.2% uranyl acetate in water, critical-point dried, coated with platinum and carbon, and transferred onto EM grids for observation.</p>
<p>PREM samples were examined using JEM 1011 transmission electron microscope (JEOL USA, Peabody, MA) operated at 100 kV. Images were acquired by an ORIUS 832.10W CCD camera (Gatan, Warrendale, PA) and presented in inverted contrast.</p>
<p>Based on the degree of invagination, the shapes of CCSs were classified into: flat CCSs with no obvious invagination; dome-shaped CCSs that had a hemispherical or less invaginated shape with visible edges of the clathrin lattice; and spherical CCSs that had a round shape with the invisible edges of clathrin lattice in 2D projection images. In most cases, the shapes were obvious in 2D PREM images. In uncertain cases, the degree of CCS invagination was determined using images tilted at ±10–20 degrees. The area of CCSs were measured using ImageJ and used for the calculation of the CCS occupancy on the plasma membrane.</p>
</sec>
</sec>


</body>
<back>
    <sec id="s5" sec-type="data-availability">
        <title>Data availability</title>
        <p>Original data are available from the corresponding authors upon request.</p>
    </sec>
    <sec id="s4i">
        <title>Online supplemental material</title>
        <p><xref ref-type="fig" rid="figs1">Fig. S1</xref> shows the western blotting results that indicate the expression levels of exogenous CCDC32. <xref ref-type="fig" rid="figs2">Fig. S2</xref> shows the representative TIRFM images of ARPE-HPV cells that stably express mRuby-CLCa and eGFP. It also shows the cohort-averaged fluorescence intensity traces of CCPs and CCP-enriched eGFP. Videos 1 and 2 shows addition time-lapse TIRFM imaging data for <xref rid="fig2" ref-type="fig">Fig. 2</xref>. Videos are accelerated 25-fold. <xref ref-type="fig" rid="figs3">Fig. S3</xref> shows that siRNA-mediated knockdown of CCDC32 did not affect AP2 protein levels. <xref ref-type="fig" rid="figs4">Fig. S4</xref> shows the fractions of CCPs in lifetime cohorts. <xref ref-type="fig" rid="figs5">Fig. S5</xref> shows additional data for <xref rid="fig4" ref-type="fig">Fig. 4</xref>. <xref ref-type="fig" rid="figs6">Fig. S6</xref> shows the AlphaFold 3.0 prediction of CCDC32 monomer structure and CCDC32-AP2-α complex structure. <xref ref-type="fig" rid="figs7">Fig. S7</xref> shows a collection of representative TIRFM images from the main text showing cells that stably express the same amount of eGFP-CCDC32(FL), eGFP, eGFP-CCDC32(Δ78-98), and eGFP-CCDC32(1-54). <xref ref-type="table" rid="tbls1">Table S1</xref> shows additional data for <xref rid="fig5" ref-type="fig">Fig. 5</xref>. <xref ref-type="table" rid="tbls2">Table S2</xref> shows a list of primers used in this study.</p>
    </sec>
<sec>
<fig id="figs1" position="float" orientation="portrait" fig-type="figure">
<label>Figure S1:</label>
<caption><p><bold>(A)</bold> Western blotting indicates similar expression levels of exogenous eGFP-CCDC32(FL), eGFP, eGFP-CCDC32(1-54) and eGFP-CCDC32(Δ78-98) in ARPE-HPV mRuby-CLCa cells. <bold>(B)</bold> siCCDC32 knocked down endogenous CCDC32 but not exogenously introduced eGFP-CCDC32(FL) from ARPE-HPV mRuby-CLCa cells. Note that the anti-CCDC32 antibody does not detect the eGFP-CCDC32(Δ78-98) as well as full-length and is unable to detect eGFP-CCDC32(1-54).</p></caption>
<graphic xlink:href="600785v4_figs1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs2" position="float" orientation="portrait" fig-type="figure">
<label>Figure S2:</label>
<caption><p><bold>(A)</bold> Representative TIRFM images of ARPE-HPV cells that stably express mRuby-CLCa and EGFP. White ROI is magnified on the right. Scale bar = 5µm. <bold>(B)</bold> Cohort-averaged fluorescence intensity traces of CCPs and CCP-enriched EGFP. Number of tracks analyzed: 46833.</p></caption>
<graphic xlink:href="600785v4_figs2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs3" position="float" orientation="portrait" fig-type="figure">
<label>Figure S3:</label>
<caption><p><bold>(A-B)</bold> siRNA-mediated knockdown of CCDC32 does not affect AP2 expression level. (A) Representative immunoblotting result of AP2 subunits from n=3 biological repeats. <bold>(B)</bold> Quantification of results from (A). Error bars indicate standard deviations. Statistical analysis is student’s t-test: ns, not significant. <bold>(C)</bold> All the four subunits of intact AP2 efficiently co-IP with eGFP-CCDC32(FL).</p></caption>
<graphic xlink:href="600785v4_figs3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs4" position="float" orientation="portrait" fig-type="figure">
<label>Figure S4:</label>
    <caption><title>Fraction of CCPs in lifetime cohorts.</title>
        <p>Data was obtained from ARPE-HPV eGFP-CLCa cells that were treated with siCCDC32. The obtained data was processed with cmeAnalysis.</p></caption>
<graphic xlink:href="600785v4_figs4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs5" position="float" orientation="portrait" fig-type="figure">
<label>Figure S5:</label>
<caption><title>CCDC32 knockdown shifts the shapes of clathrin-coated structures.</title><p>(A-B) Representative PREM images of ARPE-HPV cells treated with control siRNA (A) or CCDC32 siRNA (B). Scale bars = 200 nm. <bold>(C-D)</bold> Quantification of the CCS shape category (C) and CCS occupancy on PM (D). Each dot represents an individual fragment of the plasma membrane; the number of plasma membrane fragments analyzed is 38 for siControl and 35 for siCCDC32 from two independent experiments. Statistical tests were performed using either unpaired t-test or Mann-Whiney test depending on normality of distributed values.</p></caption>
<graphic xlink:href="600785v4_figs5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs6" position="float" orientation="portrait" fig-type="figure">
<label>Figure S6:</label>
<caption><title>The sequence and structure of CCDC32.</title>
<p>(<bold>A</bold>) Amino acid sequence of CCDC32. Blue font: canonical AP2 binding motifs; red font: predicted coiled-coil domain (aa78-98). (<bold>B</bold>) AlphaFold 3.0 modelling of full-length CCDC32 (<xref ref-type="bibr" rid="c29">Jumper et al., 2021</xref>; <xref ref-type="bibr" rid="c64">Varadi et al., 2021</xref>). Residues with pLDDT &gt; 0.8 are labelled in red. <bold>(C)</bold> co-IP of eGFP-CCDC32 did not pulldown endogenous CCDC32. Red-cycled area was overexposed on the right. <bold>(D-E)</bold> AlphaFold 3.0 modelling of CCDC32 interaction with AP2-α (gene: AP2A2). For all panels, CCDC32 is colored by pLDDT and AP2-α is grey. (D) CCDC32-AP2A2 complex. CCDC32 residues with pLDDT &gt; 0.7 are labelled in red. (E-F) Close up view of CCDC32-AP2A2 complex near CCDC32 residues (E) 12-28, 37-43 and (F) 66-91. Hydrophobic CCDC32 and AP2-α residues at the interface are labelled in red and black, respectively. Two canonical α-AD binding motifs in CCDC32 (<sup>17</sup>DLW<sup>19</sup> and <sup>39</sup>FSDSF<sup>43</sup> can be docked on the AP2 appendage domain with high confidence; aa78-98 docks with high confidence to an alpha helix in the α-subunit encoded by aa418-438. Alphafold 3.0 modelling was performed using Alphafold Server (<xref ref-type="bibr" rid="c2">Abramson et al., 2024</xref>) and structure images were generated using ChimeraX (<xref ref-type="bibr" rid="c41">Meng et al., 2023</xref>).</p></caption>
<graphic xlink:href="600785v4_figs6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs7" position="float" orientation="portrait" fig-type="figure">
<label>Figure S7:</label>
    <caption><title>A collection of representative TIRFM images from the main text showing cells that stably express the same amount of eGFP-CCDC32(FL), eGFP, eGFP-CCDC32(Δ78-98), and eGFP-CCDC32(1-54).</title>
    <p>Diffuse PM fluorescence is greatest for eGFP-CCDC32(FL), diminished, but detectable for eGFP-CCDC32(Δ78-98), but absent for eGFP-CCDC32(1-54) and control eGFP. Scale bar = 5µm. Blue dashed line indicates the background PM fluorescence of eGFP.</p></caption>
<graphic xlink:href="600785v4_figs7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<table-wrap id="tbls1" orientation="portrait" position="float">
<label>Table S1:</label>
<caption><title>ID and abundances of key proteins detected in IP samples by Mass Spectroscopy analysis.</title><p>#1-#3: 3 independent repeats of control IPs; #4-#6: 3 independent repeats of AP2-α-eGFP IPs.</p></caption>
<graphic xlink:href="600785v4_tbls1.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
<table-wrap id="tbls2" orientation="portrait" position="float">
<label>Table S2:</label>
<caption><title>List of primers.</title></caption>
<graphic xlink:href="600785v4_tbls2.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We thank the UTSW proteomics core facility for their help with sample processing and analysis. We thank Justin Bi for PREM analysis. We thank Zhenyang Chen for active participation in protein preparation. This work is supported by the National Natural Science Foundation of China (Grant No. 32200564 to Z.C.), the Natural Science Foundation of Hunan Province, China (Grant No. 2024JJ2045), the National Institutes of Health grants R35 GM 140832 to T.S., and the National Institutes of Health grant GM73165 to S.L.S.</p>
</ack>
<sec id="d1e1554" sec-type="additional-information">
<title>Additional information</title>
<sec id="s6">
<title>Author contributions</title>
<p>Z. Chen, Z. Yang, and C. Yang designed the experiments. Z. Chen, Z. Yang, C. Yang, T. Svitkina and S.L. Schmid interpreted the results and wrote the manuscript with input from all authors. Z. Yang, Y. Li and Z. Huang performed the TIRF and Epi-TIRF microscope imaging and data analysis. Z. Yang performed the co-IP, GST pull-down assays and TfnR uptake assays. C. Yang performed the PREM experiments. P. Xu performed FACS sorting. L. Han drew the cartoon illustrations. J. Pak did the AlphaFold3 modeling.</p>
</sec>
</sec>
<sec id="suppd1e1554" sec-type="supplementary-material">
<title>Additional files</title>
<supplementary-material id="d1e1538">
<label>Video1</label>
    <caption><title>Time-lapse TIRFM imaging of ARPE-HPV eGFP-CLCa cells that were treated with control siRNA. Images were obtained at 1 frame/s and collected for 7.5 min. Video is accelerated 25-fold.</title></caption>
<media xlink:href="supplements/600785_file02.avi"/>
</supplementary-material>
<supplementary-material id="d1e1545">
<label>Video2</label>
    <caption><title>Time-lapse TIRFM imaging of ARPE-HPV eGFP-CLCa cells that were treated with CCDC32 siRNA. Images were obtained at 1 frame/s and collected for 7.5 min. Video is accelerated 25-fold.</title></caption>
<media xlink:href="supplements/600785_file03.avi"/>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abdalla</surname>, <given-names>E.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Alawi</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Meinecke</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Kutsche</surname></string-name>, and <string-name><given-names>F.L.</given-names> <surname>Harms</surname></string-name></person-group>. <year>2022</year>. <article-title>Cardiofacioneurodevelopmental syndrome: Report of a novel patient and expansion of the phenotype</article-title>. <source>Am J Med Genet A</source>. <volume>188</volume>:<fpage>2448</fpage>–<lpage>2453</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abramson</surname>, <given-names>J.</given-names></string-name>, <string-name><given-names>J.</given-names> <surname>Adler</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Dunger</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Evans</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Green</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Pritzel</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Ronneberger</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Willmore</surname></string-name>, <string-name><given-names>A.J.</given-names> <surname>Ballard</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Bambrick</surname></string-name>, <string-name><given-names>S.W.</given-names> <surname>Bodenstein</surname></string-name>, <string-name><given-names>D.A.</given-names> <surname>Evans</surname></string-name>, <string-name><given-names>C.-C.</given-names> <surname>Hung</surname></string-name>, <string-name><given-names>M.</given-names> <surname>O’Neill</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Reiman</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Tunyasuvunakool</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Žemgulytė</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Arvaniti</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Beattie</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Bertolli</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Bridgland</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Cherepanov</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Congreve</surname></string-name>, <string-name><given-names>A.I.</given-names> <surname>Cowen-Rivers</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Cowie</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Figurnov</surname></string-name>, <string-name><given-names>F.B.</given-names> <surname>Fuchs</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Gladman</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Jain</surname></string-name>, <string-name><given-names>Y.A.</given-names> <surname>Khan</surname></string-name>, <string-name><given-names>C.M.R.</given-names> <surname>Low</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Perlin</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Potapenko</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Savy</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Singh</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Stecula</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Thillaisundaram</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Tong</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Yakneen</surname></string-name>, <string-name><given-names>E.D.</given-names> <surname>Zhong</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Zielinski</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Žídek</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Bapst</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Kohli</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Jaderberg</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Hassabis</surname></string-name>, and <string-name><given-names>J.M.</given-names> <surname>Jumper</surname></string-name></person-group>. <year>2024</year>. <article-title>Accurate structure prediction of biomolecular interactions with AlphaFold 3</article-title>. <source>Nature</source>. <volume>630</volume>:<fpage>493</fpage>–<lpage>500</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aguet</surname>, <given-names>F.</given-names></string-name>, <string-name><given-names>Costin N.</given-names> <surname>Antonescu</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Mettlen</surname></string-name>, <string-name><given-names>Sandra L.</given-names> <surname>Schmid</surname></string-name>, and <string-name><given-names>G.</given-names> <surname>Danuser</surname></string-name></person-group>. <year>2013</year>. <article-title>Advances in Analysis of Low Signal-to-Noise Images Link Dynamin and AP2 to the Functions of an Endocytic Checkpoint</article-title>. <source>Developmental Cell</source>. <volume>26</volume>:<fpage>279</fpage>–<lpage>291</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arrigo</surname>, <given-names>A.B.</given-names></string-name>, and <string-name><given-names>J.I.</given-names> <surname>Lin</surname></string-name></person-group>. <year>2021</year>. <article-title>Endocytic Protein Defects in the Neural Crest Cell Lineage and Its Pathway Are Associated with Congenital Heart Defects</article-title>. <source>Int J Mol Sci</source>. <volume>22</volume>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baschieri</surname>, <given-names>F.</given-names></string-name>, <string-name><given-names>K.</given-names> <surname>Porshneva</surname></string-name>, and <string-name><given-names>G.</given-names> <surname>Montagnac</surname></string-name></person-group>. <year>2020</year>. <article-title>Frustrated clathrin-mediated endocytosis – causes and possible functions</article-title>. <source>Journal of Cell Science</source>. <volume>133</volume>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bhave</surname>, <given-names>M.</given-names></string-name>, <string-name><given-names>R.E.</given-names> <surname>Mino</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>H.M.</given-names> <surname>Grossman</surname></string-name>, <string-name><given-names>A.M.</given-names> <surname>Lakoduk</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Danuser</surname></string-name>, <string-name><given-names>S.L.</given-names> <surname>Schmid</surname></string-name>, and <string-name><given-names>M.</given-names> <surname>Mettlen</surname></string-name></person-group>. <year>2020</year>. <article-title>Functional characterization of 67 endocytic accessory proteins using multiparametric quantitative analysis of CCP dynamics</article-title>. <source>Proc Natl Acad Sci U S A</source>. <volume>117</volume>:<fpage>31591</fpage>–<lpage>31602</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blue</surname>, <given-names>R.E.</given-names></string-name>, <string-name><given-names>E.G.</given-names> <surname>Curry</surname></string-name>, <string-name><given-names>N.M.</given-names> <surname>Engels</surname></string-name>, <string-name><given-names>E.Y.</given-names> <surname>Lee</surname></string-name>, and <string-name><given-names>J.</given-names> <surname>Giudice</surname></string-name></person-group>. <year>2018</year>. <article-title>How alternative splicing affects membrane-trafficking dynamics</article-title>. <source>Journal of Cell Science</source>. <volume>131</volume>:<fpage>jcs216465</fpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Busch</surname>, <given-names>D.J.</given-names></string-name>, <string-name><given-names>J.R.</given-names> <surname>Houser</surname></string-name>, <string-name><given-names>C.C.</given-names> <surname>Hayden</surname></string-name>, <string-name><given-names>M.B.</given-names> <surname>Sherman</surname></string-name>, <string-name><given-names>E.M.</given-names> <surname>Lafer</surname></string-name>, and <string-name><given-names>J.C.</given-names> <surname>Stachowiak</surname></string-name></person-group>. <year>2015</year>. <article-title>Intrinsically disordered proteins drive membrane curvature</article-title>. <source>Nat Commun</source>. <volume>6</volume>:<fpage>7875</fpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>, <given-names>Z.</given-names></string-name>, <string-name><given-names>R.E.</given-names> <surname>Mino</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Mettlen</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Michaely</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Bhave</surname></string-name>, <string-name><given-names>D.K.</given-names> <surname>Reed</surname></string-name>, and <string-name><given-names>S.L.</given-names> <surname>Schmid</surname></string-name></person-group>. <year>2020</year>. <article-title>Wbox2: A clathrin terminal domain–derived peptide inhibitor of clathrin-mediated endocytosis</article-title>. <source>Journal of Cell Biology</source>. <volume>219</volume>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>, <given-names>Z.</given-names></string-name>, and <string-name><given-names>S.L.</given-names> <surname>Schmid</surname></string-name></person-group>. <year>2020</year>. <article-title>Evolving models for assembling and shaping clathrin-coated pits</article-title>. <source>Journal of Cell Biology</source>. <volume>219</volume>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cho</surname>, <given-names>N.H.</given-names></string-name>, <string-name><given-names>K.C.</given-names> <surname>Cheveralls</surname></string-name>, <string-name><given-names>A.D.</given-names> <surname>Brunner</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Kim</surname></string-name>, <string-name><given-names>A.C.</given-names> <surname>Michaelis</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Raghavan</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Kobayashi</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Savy</surname></string-name>, <string-name><given-names>J.Y.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Canaj</surname></string-name>, <string-name><given-names>J.Y.S.</given-names> <surname>Kim</surname></string-name>, <string-name><given-names>E.M.</given-names> <surname>Stewart</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Gnann</surname></string-name>, <string-name><given-names>F.</given-names> <surname>McCarthy</surname></string-name>, <string-name><given-names>J.P.</given-names> <surname>Cabrera</surname></string-name>, <string-name><given-names>R.M.</given-names> <surname>Brunetti</surname></string-name>, <string-name><given-names>B.B.</given-names> <surname>Chhun</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Dingle</surname></string-name>, <string-name><given-names>M.Y.</given-names> <surname>Hein</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Huang</surname></string-name>, <string-name><given-names>S.B.</given-names> <surname>Mehta</surname></string-name>, <string-name><given-names>J.S.</given-names> <surname>Weissman</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Gómez-Sjöberg</surname></string-name>, <string-name><given-names>D.N.</given-names> <surname>Itzhak</surname></string-name>, <string-name><given-names>L.A.</given-names> <surname>Royer</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Mann</surname></string-name>, and <string-name><given-names>M.D.</given-names> <surname>Leonetti</surname></string-name></person-group>. <year>2022</year>. <article-title>OpenCell: Endogenous tagging for the cartography of human cellular organization</article-title>. <source>Science</source>. <volume>375</volume>:<fpage>eabi6983</fpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Collins</surname>, <given-names>B.M.</given-names></string-name>, <string-name><given-names>A.J.</given-names> <surname>McCoy</surname></string-name>, <string-name><given-names>H.M.</given-names> <surname>Kent</surname></string-name>, <string-name><given-names>P.R.</given-names> <surname>Evans</surname></string-name>, and <string-name><given-names>D.J.</given-names> <surname>Owen</surname></string-name></person-group>. <year>2002</year>. <article-title>Molecular architecture and functional model of the endocytic AP2 complex</article-title>. <source>Cell</source>. <volume>109</volume>:<fpage>523</fpage>–<lpage>535</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Conner</surname>, <given-names>S.D.</given-names></string-name>, and <string-name><given-names>S.L.</given-names> <surname>Schmid</surname></string-name></person-group>. <year>2003</year>. <article-title>Differential requirements for AP-2 in clathrin-mediated endocytosis</article-title>. <source>J Cell Biol</source>. <volume>162</volume>:<fpage>773</fpage>–<lpage>779</lpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dean</surname>, <given-names>K.M.</given-names></string-name>, <string-name><given-names>P.</given-names> <surname>Roudot</surname></string-name>, <string-name><given-names>C.R.</given-names> <surname>Reis</surname></string-name>, <string-name><given-names>E.S.</given-names> <surname>Welf</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Mettlen</surname></string-name>, and <string-name><given-names>R.</given-names> <surname>Fiolka</surname></string-name></person-group>. <year>2016</year>. <article-title>Diagonally Scanned Light-Sheet Microscopy for Fast Volumetric Imaging of Adherent Cells</article-title>. <source>Biophys J</source>. <volume>110</volume>:<fpage>1456</fpage>–<lpage>1465</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DeMari</surname>, <given-names>J.</given-names></string-name>, <string-name><given-names>C.</given-names> <surname>Mroske</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Tang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Nimeh</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Miller</surname></string-name>, and <string-name><given-names>R.R.</given-names> <surname>Lebel</surname></string-name></person-group>. <year>2016</year>. <article-title>CLTC as a clinically novel gene associated with multiple malformations and developmental delay</article-title>. <source>American Journal of Medical Genetics Part A</source>. <volume>170</volume>:<fpage>958</fpage>–<lpage>966</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Elkin</surname>, <given-names>S.R.</given-names></string-name>, <string-name><given-names>N.</given-names> <surname>Bendris</surname></string-name>, <string-name><given-names>C.R.</given-names> <surname>Reis</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Xie</surname></string-name>, <string-name><given-names>K.E.</given-names> <surname>Huffman</surname></string-name>, <string-name><given-names>J.D.</given-names> <surname>Minna</surname></string-name>, and <string-name><given-names>S.L.</given-names> <surname>Schmid</surname></string-name></person-group>. <year>2015</year>. <article-title>A Systematic Analysis Reveals Heterogeneous Changes in the Endocytic Activities of Cancer Cells</article-title>. <source>Cancer Research</source>. <volume>75</volume>:<fpage>4640</fpage>–<lpage>4650</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ferguson</surname>, <given-names>M.L.</given-names></string-name>, <string-name><given-names>K.</given-names> <surname>Prasad</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Boukari</surname></string-name>, <string-name><given-names>D.L.</given-names> <surname>Sackett</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Krueger</surname></string-name>, <string-name><given-names>E.M.</given-names> <surname>Lafer</surname></string-name>, and <string-name><given-names>R.</given-names> <surname>Nossal</surname></string-name></person-group>. <year>2008</year>. <article-title>Clathrin triskelia show evidence of molecular flexibility</article-title>. <source>Biophys J</source>. <volume>95</volume>:<fpage>1945</fpage>–<lpage>1955</lpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><string-name><surname>Gilles Moulay</surname>, <given-names>J.L.</given-names></string-name>, <string-name><surname>Mégane Lemaître</surname>, <given-names>Marc</given-names></string-name> <string-name><surname>Bitoun</surname>, <given-names>Denis</given-names></string-name> <string-name><surname>Furling</surname>, <given-names>Stéphane</given-names></string-name> <string-name><surname>Vassilopoulos</surname></string-name></person-group>. <year>2019</year>. <article-title>Revealing alternative splicing control of clathrin structural plasticity in health and disease</article-title>. In <conf-name>EMBO Conference Abstract</conf-name>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>González-Gaitán</surname>, <given-names>M.</given-names></string-name>, and <string-name><given-names>H.</given-names> <surname>Jäckle</surname></string-name></person-group>. <year>1997</year>. <article-title>Role of Drosophila alpha-adaptin in presynaptic vesicle recycling</article-title>. <source>Cell</source>. <volume>88</volume>:<fpage>767</fpage>–<lpage>776</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gorvin</surname>, <given-names>C.M.</given-names></string-name>, <string-name><given-names>A.</given-names> <surname>Rogers</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Stewart</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Paudyal</surname></string-name>, <string-name><given-names>T.A.</given-names> <surname>Hough</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Teboul</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Wells</surname></string-name>, <string-name><given-names>S.D.</given-names> <surname>Brown</surname></string-name>, <string-name><given-names>R.D.</given-names> <surname>Cox</surname></string-name>, and <string-name><given-names>R.V.</given-names> <surname>Thakker</surname></string-name></person-group>. <year>2017</year>. <article-title>N-ethyl-N-nitrosourea-Induced Adaptor Protein 2 Sigma Subunit 1 (Ap2s1) Mutations Establish Ap2s1 Loss-of-Function Mice</article-title>. <source>JBMR Plus</source>. <volume>1</volume>:<fpage>3</fpage>–<lpage>15</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grove</surname>, <given-names>J.</given-names></string-name>, <string-name><given-names>D.J.</given-names> <surname>Metcalf</surname></string-name>, <string-name><given-names>A.E.</given-names> <surname>Knight</surname></string-name>, <string-name><given-names>S.T.</given-names> <surname>Wavre-Shapton</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Sun</surname></string-name>, <string-name><given-names>E.D.</given-names> <surname>Protonotarios</surname></string-name>, <string-name><given-names>L.D.</given-names> <surname>Griffin</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Lippincott-Schwartz</surname></string-name>, and <string-name><given-names>M.</given-names> <surname>Marsh</surname></string-name></person-group>. <year>2014</year>. <article-title>Flat clathrin lattices: stable features of the plasma membrane</article-title>. <source>Mol Biol Cell</source>. <volume>25</volume>:<fpage>3581</fpage>–<lpage>3594</lpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gu</surname>, <given-names>M.</given-names></string-name>, <string-name><given-names>Q.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Watanabe</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Sun</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Hollopeter</surname></string-name>, <string-name><given-names>B.D.</given-names> <surname>Grant</surname></string-name>, and <string-name><given-names>E.M.</given-names> <surname>Jorgensen</surname></string-name></person-group>. <year>2013</year>. <article-title>AP2 hemicomplexes contribute independently to synaptic vesicle endocytosis</article-title>. <source>eLife</source>. <volume>2</volume>:<elocation-id>e00190</elocation-id>. <pub-id pub-id-type="doi">10.7554/eLife.00190</pub-id></mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hamdan</surname>, <given-names>F.F.</given-names></string-name>, <string-name><given-names>C.T.</given-names> <surname>Myers</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Cossette</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Lemay</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Spiegelman</surname></string-name>, <string-name><given-names>A.D.</given-names> <surname>Laporte</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Nassif</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Diallo</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Monlong</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Cadieux-Dion</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Dobrzeniecka</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Meloche</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Retterer</surname></string-name>, <string-name><given-names>M.T.</given-names> <surname>Cho</surname></string-name>, <string-name><given-names>J.A.</given-names> <surname>Rosenfeld</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Bi</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Massicotte</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Miguet</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Brunga</surname></string-name>, <string-name><given-names>B.M.</given-names> <surname>Regan</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Mo</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Tam</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Schneider</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Hollingsworth</surname></string-name>, <string-name><given-names>D.R.</given-names> <surname>FitzPatrick</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Donaldson</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Canham</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Blair</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Kerr</surname></string-name>, <string-name><given-names>A.E.</given-names> <surname>Fry</surname></string-name>, <string-name><given-names>R.H.</given-names> <surname>Thomas</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Shelagh</surname></string-name>, <string-name><given-names>J.A.</given-names> <surname>Hurst</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Brittain</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Blyth</surname></string-name>, <string-name><given-names>R.R.</given-names> <surname>Lebel</surname></string-name>, <string-name><given-names>E.H.</given-names> <surname>Gerkes</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Davis-Keppen</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Stein</surname></string-name>, <string-name><given-names>W.K.</given-names> <surname>Chung</surname></string-name>, <string-name><given-names>S.J.</given-names> <surname>Dorison</surname></string-name>, <string-name><given-names>P.J.</given-names> <surname>Benke</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Fassi</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Corsten-Janssen</surname></string-name>, <string-name><given-names>E.-J.</given-names> <surname>Kamsteeg</surname></string-name>, <string-name><given-names>F.T.</given-names> <surname>Mau-Them</surname></string-name>, <string-name><given-names>A.-L.</given-names> <surname>Bruel</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Verloes</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Õunap</surname></string-name>, <string-name><given-names>M.H.</given-names> <surname>Wojcik</surname></string-name>, <string-name><given-names>D.V.F.</given-names> <surname>Albert</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Venkateswaran</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Ware</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Jones</surname></string-name>, <string-name><given-names>Y.-C.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>S.S.</given-names> <surname>Mohammad</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Bizargity</surname></string-name>, <string-name><given-names>C.A.</given-names> <surname>Bacino</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Leuzzi</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Martinelli</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Dallapiccola</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Tartaglia</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Blumkin</surname></string-name>, <string-name><given-names>K.J.</given-names> <surname>Wierenga</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Purcarin</surname></string-name>, <string-name><given-names>J.J.</given-names> <surname>O’Byrne</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Stockler</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Lehman</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Keren</surname></string-name>, <string-name><given-names>M.-C.</given-names> <surname>Nougues</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Mignot</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Auvin</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Nava</surname></string-name>, <string-name><given-names>S.M.</given-names> <surname>Hiatt</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Bebin</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Shao</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Scaglia</surname></string-name>, <string-name><given-names>S.R.</given-names> <surname>Lalani</surname></string-name>, <string-name><given-names>R.E.</given-names> <surname>Frye</surname></string-name>, <string-name><given-names>I.T.</given-names> <surname>Jarjour</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Jacques</surname></string-name>, <string-name><given-names>R.-M.</given-names> <surname>Boucher</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Riou</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Srour</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Carmant</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Lortie</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Major</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Diadori</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Dubeau</surname></string-name>, <string-name><given-names>G.</given-names> <surname>D’Anjou</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Bourque</surname></string-name>, <string-name><given-names>S.F.</given-names> <surname>Berkovic</surname></string-name>, <string-name><given-names>L.G.</given-names> <surname>Sadleir</surname></string-name>, <string-name><given-names>P.M.</given-names> <surname>Campeau</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Kibar</surname></string-name>, <string-name><given-names>R.G.</given-names> <surname>Lafrenière</surname></string-name>, <string-name><given-names>S.L.</given-names> <surname>Girard</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Mercimek-Mahmutoglu</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Boelman</surname></string-name>, <string-name><given-names>G.A.</given-names> <surname>Rouleau</surname></string-name>, <etal>et al.</etal></person-group> <year>2017</year>. <article-title>High Rate of Recurrent De Novo Mutations in Developmental and Epileptic Encephalopathies</article-title>. <source>The American Journal of Human Genetics</source>. <volume>101</volume>:<fpage>664</fpage>–<lpage>685</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harel</surname>, <given-names>T.</given-names></string-name>, <string-name><given-names>J.N.</given-names> <surname>Griffin</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Arbogast</surname></string-name>, <string-name><given-names>T.O.</given-names> <surname>Monroe</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Palombo</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Martinelli</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Seri</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Pippucci</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Elpeleg</surname></string-name>, and <string-name><given-names>N.</given-names> <surname>Katsanis</surname></string-name></person-group>. <year>2020</year>. <article-title>Loss of function mutations in CCDC32 cause a congenital syndrome characterized by craniofacial, cardiac and neurodevelopmental anomalies</article-title>. <source>Human Molecular Genetics</source>. <volume>29</volume>:<fpage>1489</fpage>–<lpage>1497</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Helbig</surname>, <given-names>I.</given-names></string-name>, <string-name><given-names>T.</given-names> <surname>Lopez-Hernandez</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Shor</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Galer</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Ganesan</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Pendziwiat</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Rademacher</surname></string-name>, <string-name><given-names>C.A.</given-names> <surname>Ellis</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Hümpfer</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Schwarz</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Seiffert</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Peeden</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Shen</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Štěrbová</surname></string-name>, <string-name><given-names>T.B.</given-names> <surname>Hammer</surname></string-name>, <string-name><given-names>R.S.</given-names> <surname>Møller</surname></string-name>, <string-name><given-names>D.N.</given-names> <surname>Shinde</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Tang</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Smith</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Poduri</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Krause</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Benninger</surname></string-name>, <string-name><given-names>K.L.</given-names> <surname>Helbig</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Haucke</surname></string-name>, and <string-name><given-names>Y.G.</given-names> <surname>Weber</surname></string-name></person-group>. <year>2019</year>. <article-title>A Recurrent Missense Variant in AP2M1 Impairs Clathrin-Mediated Endocytosis and Causes Developmental and Epileptic Encephalopathy</article-title>. <source>Am J Hum Genet</source>. <volume>104</volume>:<fpage>1060</fpage>–<lpage>1072</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Henne</surname>, <given-names>W.M.</given-names></string-name>, <string-name><given-names>E.</given-names> <surname>Boucrot</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Meinecke</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Evergren</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Vallis</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Mittal</surname></string-name>, and <string-name><given-names>H.T.</given-names> <surname>McMahon</surname></string-name></person-group>. <year>2010</year>. <article-title>FCHo proteins are nucleators of clathrin-mediated endocytosis</article-title>. <source>Science</source>. <volume>328</volume>:<fpage>1281</fpage>–<lpage>1284</lpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jackson</surname>, <given-names>L.P.</given-names></string-name>, <string-name><given-names>B.T.</given-names> <surname>Kelly</surname></string-name>, <string-name><given-names>A.J.</given-names> <surname>McCoy</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Gaffry</surname></string-name>, <string-name><given-names>L.C.</given-names> <surname>James</surname></string-name>, <string-name><given-names>B.M.</given-names> <surname>Collins</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Höning</surname></string-name>, <string-name><given-names>P.R.</given-names> <surname>Evans</surname></string-name>, and <string-name><given-names>D.J.</given-names> <surname>Owen</surname></string-name></person-group>. <year>2010</year>. <article-title>A large-scale conformational change couples membrane recruitment to cargo binding in the AP2 clathrin adaptor complex</article-title>. <source>Cell</source>. <volume>141</volume>:<fpage>1220</fpage>–<lpage>1229</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jaqaman</surname>, <given-names>K.</given-names></string-name>, <string-name><given-names>D.</given-names> <surname>Loerke</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Mettlen</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Kuwata</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Grinstein</surname></string-name>, <string-name><given-names>S.L.</given-names> <surname>Schmid</surname></string-name>, and <string-name><given-names>G.</given-names> <surname>Danuser</surname></string-name></person-group>. <year>2008</year>. <article-title>Robust single-particle tracking in live-cell time-lapse sequences</article-title>. <source>Nat Methods</source>. <volume>5</volume>:<fpage>695</fpage>–<lpage>702</lpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jumper</surname>, <given-names>J.</given-names></string-name>, <string-name><given-names>R.</given-names> <surname>Evans</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Pritzel</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Green</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Figurnov</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Ronneberger</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Tunyasuvunakool</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Bates</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Žídek</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Potapenko</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Bridgland</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Meyer</surname></string-name>, <string-name><given-names>S.A.A.</given-names> <surname>Kohl</surname></string-name>, <string-name><given-names>A.J.</given-names> <surname>Ballard</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Cowie</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Romera-Paredes</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Nikolov</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Jain</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Adler</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Back</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Petersen</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Reiman</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Clancy</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Zielinski</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Steinegger</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Pacholska</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Berghammer</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Bodenstein</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Silver</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Vinyals</surname></string-name>, <string-name><given-names>A.W.</given-names> <surname>Senior</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Kavukcuoglu</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Kohli</surname></string-name>, and <string-name><given-names>D.</given-names> <surname>Hassabis</surname></string-name></person-group>. <year>2021</year>. <article-title>Highly accurate protein structure prediction with AlphaFold</article-title>. <source>Nature</source>. <volume>596</volume>:<fpage>583</fpage>–<lpage>589</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jung</surname>, <given-names>S.</given-names></string-name>, <string-name><given-names>T.</given-names> <surname>Maritzen</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Wichmann</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Jing</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Neef</surname></string-name>, <string-name><given-names>N.H.</given-names> <surname>Revelo</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Al-Moyed</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Meese</surname></string-name>, <string-name><given-names>S.M.</given-names> <surname>Wojcik</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Panou</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Bulut</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Schu</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Ficner</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Reisinger</surname></string-name>, <string-name><given-names>S.O.</given-names> <surname>Rizzoli</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Neef</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Strenzke</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Haucke</surname></string-name>, and <string-name><given-names>T.</given-names> <surname>Moser</surname></string-name></person-group>. <year>2015</year>. <article-title>Disruption of adaptor protein 2μ (AP-2μ) in cochlear hair cells impairs vesicle reloading of synaptic release sites and hearing</article-title>. <source>EMBO J</source>. <volume>34</volume>:<fpage>2686</fpage>–<lpage>2702</lpage>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaksonen</surname>, <given-names>M.</given-names></string-name>, and <string-name><given-names>A.</given-names> <surname>Roux</surname></string-name></person-group>. <year>2018</year>. <article-title>Mechanisms of clathrin-mediated endocytosis</article-title>. <source>Nature Reviews Molecular Cell Biology</source>. <volume>19</volume>:<fpage>313</fpage>–<lpage>326</lpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kirchhausen</surname>, <given-names>T.</given-names></string-name>, <string-name><given-names>D.</given-names> <surname>Owen</surname></string-name>, and <string-name><given-names>S.C.</given-names> <surname>Harrison</surname></string-name></person-group>. <year>2014</year>. <article-title>Molecular structure, function, and dynamics of clathrin-mediated membrane traffic</article-title>. <source>Cold Spring Harb Perspect Biol</source>. <volume>6</volume>:<fpage>a016725</fpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kutner</surname>, <given-names>R.H.</given-names></string-name>, <string-name><given-names>X.Y.</given-names> <surname>Zhang</surname></string-name>, and <string-name><given-names>J.</given-names> <surname>Reiser</surname></string-name></person-group>. <year>2009</year>. <article-title>Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors</article-title>. <source>Nature Protocols</source>. <volume>4</volume>:<fpage>495</fpage>–<lpage>505</lpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>B.</given-names></string-name>, <string-name><given-names>L.</given-names> <surname>Ma</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Yuan</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Jiang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Pan</surname></string-name>, and <string-name><given-names>Q.</given-names> <surname>Tan</surname></string-name></person-group>. <year>2018</year>. <article-title>Associations of genetic variants in endocytic trafficking of epidermal growth factor receptor super pathway with risk of nonsyndromic cleft lip with or without cleft palate</article-title>. <source>Mol Genet Genomic Med</source>. <volume>6</volume>:<fpage>1157</fpage>–<lpage>1167</lpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>Q.</given-names></string-name>, <string-name><given-names>Y.</given-names> <surname>Laumonnier</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Syrovets</surname></string-name>, and <string-name><given-names>T.</given-names> <surname>Simmet</surname></string-name></person-group>. <year>2011</year>. <article-title>Yeast two-hybrid screening of proteins interacting with plasmin receptor subunit: C-terminal fragment of annexin A2</article-title>. <source>Acta Pharmacol Sin</source>. <volume>32</volume>:<fpage>1411</fpage>–<lpage>1418</lpage>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>W.</given-names></string-name>, <string-name><given-names>R.</given-names> <surname>Puertollano</surname></string-name>, <string-name><given-names>J.S.</given-names> <surname>Bonifacino</surname></string-name>, <string-name><given-names>P.A.</given-names> <surname>Overbeek</surname></string-name>, and <string-name><given-names>E.T.</given-names> <surname>Everett</surname></string-name></person-group>. <year>2010</year>. <article-title>Disruption of the murine Ap2β1 gene causes nonsyndromic cleft palate</article-title>. <source>Cleft Palate Craniofac J</source>. <volume>47</volume>:<fpage>566</fpage>–<lpage>573</lpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Loerke</surname>, <given-names>D.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Mettlen</surname></string-name>, <string-name><given-names>S.L.</given-names> <surname>Schmid</surname></string-name>, and <string-name><given-names>G.</given-names> <surname>Danuser</surname></string-name></person-group>. <year>2011</year>. <article-title>Measuring the Hierarchy of Molecular Events During Clathrin-Mediated Endocytosis</article-title>. <source>Traffic</source>. <volume>12</volume>:<fpage>815</fpage>–<lpage>825</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lykke-Andersen</surname>, <given-names>S.</given-names></string-name>, and <string-name><given-names>T.H.</given-names> <surname>Jensen</surname></string-name></person-group>. <year>2015</year>. <article-title>Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes</article-title>. <source>Nat Rev Mol Cell Biol</source>. <volume>16</volume>:<fpage>665</fpage>–<lpage>677</lpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Manti</surname>, <given-names>F.</given-names></string-name>, <string-name><given-names>F.</given-names> <surname>Nardecchia</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Barresi</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Venditti</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Pizzi</surname></string-name>, <string-name><given-names>F.F.</given-names> <surname>Hamdan</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Blau</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Burlina</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Tartaglia</surname></string-name>, and <string-name><given-names>V.</given-names> <surname>Leuzzi</surname></string-name></person-group>. <year>2019</year>. <article-title>Neurotransmitter trafficking defect in a patient with clathrin (CLTC) variation presenting with intellectual disability and early-onset parkinsonism</article-title>. <source>Parkinsonism &amp; Related Disorders</source>. <volume>61</volume>:<fpage>207</fpage>–<lpage>210</lpage>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McMahon</surname>, <given-names>H.T.</given-names></string-name>, and <string-name><given-names>E.</given-names> <surname>Boucrot</surname></string-name></person-group>. <year>2011</year>. <article-title>Molecular mechanism and physiological functions of clathrin-mediated endocytosis</article-title>. <source>Nat Rev Mol Cell Biol</source>. <volume>12</volume>:<fpage>517</fpage>–<lpage>533</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meng</surname>, <given-names>E.C.</given-names></string-name>, <string-name><given-names>T.D.</given-names> <surname>Goddard</surname></string-name>, <string-name><given-names>E.F.</given-names> <surname>Pettersen</surname></string-name>, <string-name><given-names>G.S.</given-names> <surname>Couch</surname></string-name>, <string-name><given-names>Z.J.</given-names> <surname>Pearson</surname></string-name>, <string-name><given-names>J.H.</given-names> <surname>Morris</surname></string-name>, and <string-name><given-names>T.E.</given-names> <surname>Ferrin</surname></string-name></person-group>. <year>2023</year>. <article-title>UCSF ChimeraX: Tools for structure building and analysis</article-title>. <source>Protein Science</source>. <volume>32</volume>:<fpage>e4792</fpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Merrifield</surname>, <given-names>C.J.</given-names></string-name>, and <string-name><given-names>M.</given-names> <surname>Kaksonen</surname></string-name></person-group>. <year>2014</year>. <article-title>Endocytic Accessory Factors and Regulation of Clathrin-Mediated Endocytosis</article-title>. <source>Cold Spring Harbor Perspectives in Biology</source>. <volume>6</volume>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Messa</surname>, <given-names>M.</given-names></string-name>, <string-name><given-names>R.</given-names> <surname>Fernández-Busnadiego</surname></string-name>, <string-name><given-names>E.W.</given-names> <surname>Sun</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Czapla</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Wrasman</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Ko</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Ross</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Wendland</surname></string-name>, and <string-name><given-names>P.</given-names> <surname>De Camilli</surname></string-name></person-group>. <year>2014</year>. <article-title>Epsin deficiency impairs endocytosis by stalling the actin-dependent invagination of endocytic clathrin-coated pits</article-title>. <source>eLife</source>. <volume>3</volume>:<elocation-id>e03311</elocation-id>. <pub-id pub-id-type="doi">10.7554/eLife.03311</pub-id></mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mettlen</surname>, <given-names>M.</given-names></string-name>, <string-name><given-names>P.H.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Srinivasan</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Danuser</surname></string-name>, and <string-name><given-names>S.L.</given-names> <surname>Schmid</surname></string-name></person-group>. <year>2018</year>. <article-title>Regulation of Clathrin-Mediated Endocytosis</article-title>. <source>Annu Rev Biochem</source>. <volume>87</volume>:<fpage>871</fpage>–<lpage>896</lpage>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mettlen</surname>, <given-names>M.</given-names></string-name>, and <string-name><given-names>G.</given-names> <surname>Danuser</surname></string-name></person-group>. <year>2014</year>. <article-title>Imaging and Modeling the Dynamics of Clathrin-Mediated Endocytosis</article-title>. <source>Cold Spring Harbor Perspectives in Biology</source>. <volume>6</volume>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mino</surname>, <given-names>R.E.</given-names></string-name>, <string-name><given-names>Z.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Mettlen</surname></string-name>, and <string-name><given-names>S.L.</given-names> <surname>Schmid</surname></string-name></person-group>. <year>2020</year>. <article-title>An internally eGFP-tagged α-adaptin is a fully functional and improved fiduciary marker for clathrin-coated pit dynamics</article-title>. <source>Traffic</source>. <volume>21</volume>:<fpage>603</fpage>–<lpage>616</lpage>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Olesen</surname>, <given-names>L.E.</given-names></string-name>, <string-name><given-names>M.G.J.</given-names> <surname>Ford</surname></string-name>, <string-name><given-names>E.M.</given-names> <surname>Schmid</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Vallis</surname></string-name>, <string-name><given-names>M.M.</given-names> <surname>Babu</surname></string-name>, <string-name><given-names>P.H.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>I.G.</given-names> <surname>Mills</surname></string-name>, <string-name><given-names>H.T.</given-names> <surname>McMahon</surname></string-name>, and <string-name><given-names>G.J.K.</given-names> <surname>Praefcke</surname></string-name></person-group>. <year>2008</year>. <article-title>Solitary and Repetitive Binding Motifs for the AP2 Complex α-Appendage in Amphiphysin and Other Accessory Proteins*</article-title>. <source>Journal of Biological Chemistry</source>. <volume>283</volume>:<fpage>5099</fpage>–<lpage>5109</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Praefcke</surname>, <given-names>G.J.</given-names></string-name>, <string-name><given-names>M.G.</given-names> <surname>Ford</surname></string-name>, <string-name><given-names>E.M.</given-names> <surname>Schmid</surname></string-name>, <string-name><given-names>L.E.</given-names> <surname>Olesen</surname></string-name>, <string-name><given-names>J.L.</given-names> <surname>Gallop</surname></string-name>, <string-name><given-names>S.Y.</given-names> <surname>Peak-Chew</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Vallis</surname></string-name>, <string-name><given-names>M.M.</given-names> <surname>Babu</surname></string-name>, <string-name><given-names>I.G.</given-names> <surname>Mills</surname></string-name>, and <string-name><given-names>H.T.</given-names> <surname>McMahon</surname></string-name></person-group>. <year>2004</year>. <article-title>Evolving nature of the AP2 alpha-appendage hub during clathrin-coated vesicle endocytosis</article-title>. <source>EMBO J</source>. <volume>23</volume>:<fpage>4371</fpage>–<lpage>4383</lpage>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reis</surname>, <given-names>C.R.</given-names></string-name>, <string-name><given-names>P.H.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Srinivasan</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Aguet</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Mettlen</surname></string-name>, and <string-name><given-names>S.L.</given-names> <surname>Schmid</surname></string-name></person-group>. <year>2015</year>. <article-title>Crosstalk between Akt/GSK3β signaling and dynamin-1 regulates clathrin-mediated endocytosis</article-title>. <source>EMBO J</source>. <volume>34</volume>:<fpage>2132</fpage>–<lpage>2146</lpage>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saffarian</surname>, <given-names>S.</given-names></string-name>, and <string-name><given-names>T.</given-names> <surname>Kirchhausen</surname></string-name></person-group>. <year>2008</year>. <article-title>Differential evanescence nanometry: live-cell fluorescence measurements with 10-nm axial resolution on the plasma membrane</article-title>. <source>Biophys J</source>. <volume>94</volume>:<fpage>2333</fpage>–<lpage>2342</lpage>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmid</surname>, <given-names>E.M.</given-names></string-name>, <string-name><given-names>M.G.J.</given-names> <surname>Ford</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Burtey</surname></string-name>, <string-name><given-names>G.J.K.</given-names> <surname>Praefcke</surname></string-name>, <string-name><given-names>S.-Y.</given-names> <surname>Peak-Chew</surname></string-name>, <string-name><given-names>I.G.</given-names> <surname>Mills</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Benmerah</surname></string-name>, and <string-name><given-names>H.T.</given-names> <surname>McMahon</surname></string-name></person-group>. <year>2006</year>. <article-title>Role of the AP2 β-Appendage Hub in Recruiting Partners for Clathrin-Coated Vesicle Assembly</article-title>. <source>PLOS Biology</source>. <volume>4</volume>:<fpage>e262</fpage>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmid</surname>, <given-names>S.L.</given-names></string-name>, and <string-name><given-names>E.</given-names> <surname>Smythe</surname></string-name></person-group>. <year>1991</year>. <article-title>Stage-specific assays for coated pit formation and coated vesicle budding in vitro</article-title>. <source>J Cell Biol</source>. <volume>114</volume>:<fpage>869</fpage>–<lpage>880</lpage>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname>, <given-names>S.M.</given-names></string-name>, and <string-name><given-names>C.J.</given-names> <surname>Smith</surname></string-name></person-group>. <year>2022</year>. <article-title>Capturing the mechanics of clathrin-mediated endocytosis</article-title>. <source>Curr Opin Struc Biol</source>. <volume>75</volume>:<fpage>102427</fpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sochacki</surname>, <given-names>K.A.</given-names></string-name>, <string-name><given-names>A.M.</given-names> <surname>Dickey</surname></string-name>, <string-name><given-names>M.-P.</given-names> <surname>Strub</surname></string-name>, and <string-name><given-names>J.W.</given-names> <surname>Taraska</surname></string-name></person-group>. <year>2017</year>. <article-title>Endocytic proteins are partitioned at the edge of the clathrin lattice in mammalian cells</article-title>. <source>Nature Cell Biology</source>. <volume>19</volume>:<fpage>352</fpage>–<lpage>361</lpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Srinivasan</surname>, <given-names>S.</given-names></string-name>, <string-name><given-names>C.J.</given-names> <surname>Burckhardt</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Bhave</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>P.H.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Danuser</surname></string-name>, and <string-name><given-names>S.L.</given-names> <surname>Schmid</surname></string-name></person-group>. <year>2018</year>. <article-title>A noncanonical role for dynamin-1 in regulating early stages of clathrin-mediated endocytosis in non-neuronal cells</article-title>. <source>PLoS Biol</source>. <volume>16</volume>:<fpage>e2005377</fpage>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Svitkina</surname>, <given-names>T</given-names></string-name></person-group>. <year>2022</year>. <article-title>Imaging Cytoskeleton Components by Electron Microscopy</article-title>. <source>Methods Mol Biol</source>. <volume>2364</volume>:<fpage>25</fpage>–<lpage>52</lpage>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Svitkina</surname>, <given-names>T.M</given-names></string-name></person-group>. <year>2017</year>. <article-title>Platinum replica electron microscopy: Imaging the cytoskeleton globally and locally</article-title>. <source>Int J Biochem Cell Biol</source>. <volume>86</volume>:<fpage>37</fpage>–<lpage>41</lpage>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sznajder</surname>, <given-names>Ł.J.</given-names></string-name>, and <string-name><given-names>M.S.</given-names> <surname>Swanson</surname></string-name></person-group>. <year>2019</year>. <article-title>Short Tandem Repeat Expansions and RNA-Mediated Pathogenesis in Myotonic Dystrophy</article-title>. <source>International Journal of Molecular Sciences</source>. <volume>20</volume>:<fpage>3365</fpage>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tagiltsev</surname>, <given-names>G.</given-names></string-name>, <string-name><given-names>C.A.</given-names> <surname>Haselwandter</surname></string-name>, and <string-name><given-names>S.</given-names> <surname>Scheuring</surname></string-name></person-group>. <year>2021</year>. <article-title>Nanodissected elastically loaded clathrin lattices relax to increased curvature</article-title>. <source>Science Advances</source>. <volume>7</volume>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Taylor</surname>, <given-names>M.J.</given-names></string-name>, <string-name><given-names>D.</given-names> <surname>Perrais</surname></string-name>, and <string-name><given-names>C.J.</given-names> <surname>Merrifield</surname></string-name></person-group>. <year>2011</year>. <article-title>A High Precision Survey of the Molecular Dynamics of Mammalian Clathrin-Mediated Endocytosis</article-title>. <source>PLOS Biology</source>. <volume>9</volume>:<fpage>e1000604</fpage>.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Traub</surname>, <given-names>L.M</given-names></string-name></person-group>. <year>2011</year>. <article-title>Regarding the Amazing Choreography of Clathrin Coats</article-title>. <source>Plos Biology</source>. <volume>9</volume>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Umasankar</surname>, <given-names>P.K.</given-names></string-name>, <string-name><given-names>L.</given-names> <surname>Ma</surname></string-name>, <string-name><given-names>J.R.</given-names> <surname>Thieman</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Jha</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Doray</surname></string-name>, <string-name><given-names>S.C.</given-names> <surname>Watkins</surname></string-name>, and <string-name><given-names>L.M.</given-names> <surname>Traub</surname></string-name></person-group>. <year>2014</year>. <article-title>A clathrin coat assembly role for the muniscin protein central linker revealed by TALEN-mediated gene editing</article-title>. <source>eLife</source>. <volume>3</volume>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Umasankar</surname>, <given-names>P.K.</given-names></string-name>, <string-name><given-names>S.</given-names> <surname>Sanker</surname></string-name>, <string-name><given-names>J.R.</given-names> <surname>Thieman</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Chakraborty</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Wendland</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Tsang</surname></string-name>, and <string-name><given-names>L.M.</given-names> <surname>Traub</surname></string-name></person-group>. <year>2012</year>. <article-title>Distinct and separable activities of the endocytic clathrin-coat components Fcho1/2 and AP-2 in developmental patterning</article-title>. <source>Nat Cell Biol</source>. <volume>14</volume>:<fpage>488</fpage>–<lpage>501</lpage>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Varadi</surname>, <given-names>M.</given-names></string-name>, <string-name><given-names>S.</given-names> <surname>Anyango</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Deshpande</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Nair</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Natassia</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Yordanova</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Yuan</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Stroe</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Wood</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Laydon</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Žídek</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Green</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Tunyasuvunakool</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Petersen</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Jumper</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Clancy</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Green</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Vora</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Lutfi</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Figurnov</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Cowie</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Hobbs</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Kohli</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Kleywegt</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Birney</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Hassabis</surname></string-name>, and <string-name><given-names>S.</given-names> <surname>Velankar</surname></string-name></person-group>. <year>2021</year>. <article-title>AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models</article-title>. <source>Nucleic Acids Research</source>. <volume>50</volume>:<fpage>D439</fpage>–<lpage>D444</lpage>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wainberg</surname>, <given-names>M.</given-names></string-name>, <string-name><given-names>R.A.</given-names> <surname>Kamber</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Balsubramani</surname></string-name>, <string-name><given-names>R.M.</given-names> <surname>Meyers</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Sinnott-Armstrong</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Hornburg</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Jiang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Chan</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Jian</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Gu</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Shcherbina</surname></string-name>, <string-name><given-names>M.M.</given-names> <surname>Dubreuil</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Spees</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Meuleman</surname></string-name>, <string-name><given-names>M.P.</given-names> <surname>Snyder</surname></string-name>, <string-name><given-names>M.C.</given-names> <surname>Bassik</surname></string-name>, and <string-name><given-names>A.</given-names> <surname>Kundaje</surname></string-name></person-group>. <year>2021</year>. <article-title>A genome-wide atlas of co-essential modules assigns function to uncharacterized genes</article-title>. <source>Nature Genetics</source>. <volume>53</volume>:<fpage>638</fpage>–<lpage>649</lpage>.</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wan</surname>, <given-names>C.</given-names></string-name>, <string-name><given-names>H.</given-names> <surname>Puscher</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Ouyang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Tian</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Yin</surname></string-name>, and <string-name><given-names>J.</given-names> <surname>Shen</surname></string-name></person-group>. <year>2024</year>. <article-title>An AAGAB-to-CCDC32 handover mechanism controls the assembly of the AP2 adaptor complex</article-title>. <source>Proc Natl Acad Sci U S A</source>. <volume>121</volume>:<fpage>e2409341121</fpage>.</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>, <given-names>X.</given-names></string-name>, <string-name><given-names>Z.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Mettlen</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Noh</surname></string-name>, <string-name><given-names>S.L.</given-names> <surname>Schmid</surname></string-name>, and <string-name><given-names>G.</given-names> <surname>Danuser</surname></string-name></person-group>. <year>2020</year>. <article-title>DASC, a sensitive classifier for measuring discrete early stages in clathrin-mediated endocytosis</article-title>. <source>eLife</source>. <volume>9</volume>:<elocation-id>e53686</elocation-id>. <pub-id pub-id-type="doi">10.7554/eLife.53686</pub-id></mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname>, <given-names>F.</given-names></string-name>, and <string-name><given-names>P.J.</given-names> <surname>Yao</surname></string-name></person-group>. <year>2009</year>. <article-title>Clathrin-mediated endocytosis and Alzheimer’s disease: An update</article-title>. <source>Ageing Res Rev</source>. <volume>8</volume>:<fpage>147</fpage>–<lpage>149</lpage>.</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>, <given-names>C.</given-names></string-name>, <string-name><given-names>P.</given-names> <surname>Colosi</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Hugelier</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Zabezhinsky</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Lakadamyali</surname></string-name>, and <string-name><given-names>T.</given-names> <surname>Svitkina</surname></string-name></person-group>. <year>2022</year>. <article-title>Actin polymerization promotes invagination of flat clathrin-coated lattices in mammalian cells by pushing at lattice edges</article-title>. <source>Nature Communications</source>. <volume>13</volume>:<fpage>6127</fpage>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107039.2.sa4</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lu</surname>
<given-names>Lei</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Nanyang Technological University</institution>
</institution-wrap>
<city>Singapore</city>
<country>Singapore</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Solid</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Valuable</kwd>
</kwd-group>
</front-stub>
<body>
<p>The manuscript presents a <bold>valuable</bold> finding that CCDC32, beyond its reported role in AP2 assembly, follows AP2 to the plasma membrane and regulates clathrin-coated pit assembly and dynamics. The authors further identify an alpha-helical region within CCDC32 that is essential for its interaction with AP2 and its cellular function. While live-cell and ultrastructural imaging data are <bold>solid</bold>, future biochemical studies will be needed to confirm the proposed CCDC32-AP2 interaction.</p>
<p>[Editors' note: this paper was reviewed by <ext-link ext-link-type="uri" xlink:href="https://www.reviewcommons.org/">Review Commons</ext-link>.]</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107039.2.sa3</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Yang et al. describes CCDC32 as a new clathrin mediated endocytosis (CME) accessory protein. The authors show that CCDC32 binds directly to AP2 via a small alpha helical region and cells depleted for this protein show defective CME. Finally, the authors show that the CCDC32 nonsense mutations found in patients with cardio-facial-neuro-developmental syndrome (CFNDS) disrupt the interaction of this protein to the AP2 complex. The results presented suggest that CCDC32 may act as both a chaperone (as recently published) and a structural component of the AP2 complex.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107039.2.sa2</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>
The authors responded to my previous concerns with additional arguments and discussion. While I do not object to the publication of this work, two critical experiments are still missing.</p>
<p>Weaknesses:</p>
<p>
First, biochemical assays using recombinant proteins should be conducted to determine whether CCDC32 binds to the full AP2 adaptor or to specific AP2 intermediates, such as hemicomplexes. The current co-IP data from mammalian cell lysates are too complex to interpret conclusively. Second, cell fractionation should be performed to assess whether, and how, CCDC32 associates with membrane-bound AP2.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107039.2.sa1</article-id>
<title-group>
<article-title>Reviewer #3 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>In this manuscript, Yang et al. characterize the endocytic accessory protein CCDC32, which has implications in cardio-facio-neuro-developmental syndrome (CFNDS). The authors clearly demonstrate that the protein CCDC32 has a role in the early stages of endocytosis, mainly through the interaction with the major endocytic adaptor protein AP2, and they identify regions taking part in this recognition. Through live cell fluorescence imaging and electron microscopy of endocytic pits, the authors characterize the lifetimes of endocytic sites, the formation rate of endocytic sites and pits and the invagination depth, in addition to transferrin receptor (TfnR) uptake experiments. Binding between CCDC32 and CCDC32 mutants to the AP2 alpha appendage domain is assessed by pull down experiments.</p>
<p>Together, these experiments allow deriving a phenotype of CCDC32 knock-down and CCDC32 mutants within endocytosis, which is a very robust system, in which defects are not so easily detected. A mutation of CCDC32, mimicking CFNDS mutations, is also addressed in this study and shown to have endocytic defects.</p>
<p>An experimental proof for the resistance of the different CCDC32 mutants to siRNA treatment would have helped to strengthen the conclusions.</p>
<p>In summary, the authors present a strong combination of techniques, assessing the impact of CCDC32 in clathrin mediated endocytosis and its binding to AP2.</p>
</body>
</sub-article>
<sub-article id="sa4" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107039.2.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Ziyan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Changsong</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Zheng</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Peiliu</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Yueping</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Han</surname>
<given-names>Lu</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peng</surname>
<given-names>Linyuan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Xiangying</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pak</surname>
<given-names>John</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Svitkina</surname>
<given-names>Tatyana</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schmid</surname>
<given-names>Sandra L</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Zhiming</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2423-101X</contrib-id></contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the original reviews</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #1 (Public review):</bold></p>
<p>This is a revision of a manuscript previously submitted to Review Commons. The authors have partially addressed my comments, mainly by expanding the introduction and discussion sections. Sandy Schmid, a leading expert on the AP2 adaptor and CME, has been added as a co-corresponding author. The main message of the manuscript remains unchanged. Through overexpression of fluorescently tagged CCDC32, the authors propose that, in addition to its established role in AP2 assembly, CCDC32 also follows AP2 to the plasma membrane and regulates CCP maturation. The manuscript presents some interesting ideas, but there are still concerns regarding data inconsistencies and gaps in the evidence.</p>
</disp-quote>
<p>With due respect, we would argue that a role for CCDC32 in AP2 assembly is hardly ‘established’.  Rather a single publication reporting its role as a co-chaperone for AAGAP appeared while our manuscript was under review.  We find some similar and some conflicting results, which are described in our revised manuscript.  However, in combination our two papers clearly show that CCDC32, a previously unrecognized endocytic accessory protein, deserves further study.</p>
<disp-quote content-type="editor-comment">
<p>(1) eGFP-CCDC32 was expressed at 5-10 times higher levels than endogenous CCDC32. This high expression can artificially drive CCDC32 to the cell surface via binding to the alpha appendage domain (AD)-an interaction that may not occur under physiological conditions.</p>
</disp-quote>
<p>While we acknowledge that overexpression of eGFP-CCDC32 could result in artificially driving it to CCPs, we do not believe this is the case for the following reasons:</p>
<p>i. The bulk of our studies (Figures 2-4) demonstrate the effects of siRNA knockdown on CCDC32 on CCP early stages of CME, and so it is likely that these functions require the presence of endogenous CCDC32 at nascent CCPs as detected with overexpressed eGFP-CCDC32 by TIRF imaging.</p>
<p>ii. At these levels of overexpression eGFP-CCDC32 fully rescues the effects of siRNA KD of endogenous CCCDC32 of Tfn uptake and CCP dynamics (Figure 6F,G). If the protein was artificially recruited to the AP2 appendage domain, one would expect it to compete with the recruitment of other EAPS to CCPs and hence exhibit defects in CCP dynamics. Indeed, we see the opposite: CCPs that are positive for eGFP-CCDC32 show normal dynamics and maturation rates, while CCPs lacking eGFP-CCDC32 are short-lived and more likely to be aborted (Figure 1C).</p>
<p>iii. We have identified two modes of binding of CCDC32 to AP2 adaptors: one is through canonical AP2-AD binding motifs, the second is through an a-helix in CCDC32 that, by modeling, docks only to the open conformation of AP2.  Overexpressed CCDC32 lacking this a-helix is not recruited to CCPs (Fig. 6 D,E), indicating that the canonical AP2 binding motifs are not sufficient to recruit CCDC32 to CCPs, even when overexpressed.</p>
<disp-quote content-type="editor-comment">
<p>(2) Which region of CCDC32 mediates alpha AD binding? Strangely, the only mutant tested in this work, Δ78-98, still binds AP2, but shifts to binding only mu and beta. If the authors claim that CCDC32 is recruited to mature AP2 via the alpha AD, then a mutant deficient in alpha AD binding should not bind AP2 at all. Such a mutant is critical for establish the model proposed in this work.</p>
</disp-quote>
<p>We understand the reviewer’s confusion and thus devoted a paragraph in the discussion to this issue.  As revealed by AlphaFold 3.0 modeling (Figure S6) binding of CCDC32 to the alpha AD likely occurs via the 2 canonical AP2-AD binding motifs encoded in CCDC32. Given the highly divergent nature of AP2-AD binding motifs, we did not identify these motifs without the AlphaFold 3.0 modeling. While these interactions could be detected by GST-pull downs, they are apparently not of sufficient affinity to recruit CCDC32 to CCPs in cells. In the text, we now describe the a-helix we identified as being essential of CCP recruitment as ‘a’ AP2 binding site on CCDC32 rather than ‘the’ AP2 binding site.  Interestingly, and also discussed, Alphafold 3.0 identifies a highly predicted docking site on a-adaptin that is only accessible in the open, cargo-bound conformation of intact AP2.  This is also consistent with the inability of CCDC32(D78-99) to bind the a:µ2 hemi-complex in cell lysates.</p>
<p>We agree that further structural studies on CCDC32’s interactions with AP2 and its targeting to CCPs will be of interest for future work.</p>
<disp-quote content-type="editor-comment">
<p>(3) The concept of hemicomplexes is introduced abruptly. What is the evidence that such hemicomplexes exist? If CCDC32 binds to hemicomplexes, this must occur in the cytosol, as only mature AP2 tetramers are recruited to the plasma membrane. The authors state that CCDC32 binds the AD of alpha but not beta, so how can the Δ78-98 mutant bind mu and beta?</p>
</disp-quote>
<p>We introduced the concept of hemicomplexes based on our unexpected (and now explicitly stated as such) finding that the CCDC32(D78-99) mutant efficiently co-IPs with a b2:µ2 hemicomplex.  As stated, the efficiency of this pulldown suggests that the presumed stable AP2 heterotetramer must indeed exist in equilibrium between the two a:s2 and b2:µ2 hemicomplexes, such that CCDC32(D78-99) can sequester and efficiently co-IP with the b2:µ2 hemicomplex.  A previous study, now cited, had shown that the b2:µ2 hemicomplex could partially rescue null mutations of a in C. elegans (PMID: 23482940).  We do not know how CCDC32 binds to the b2:µ2 hemicomplex and we did not detect these interactions using AlphaFold 3.0. However, these interactions could be indirect and involve the AAGAB chaperone.  It is also likely, based on the results of Wan et al. (PMID: 39145939), that the binding is through the µ2 subunit rather than b2. As mentioned above, and in our Discussion, further studies are needed to define the complex and multi-faceted nature of CCDC32-AP2 interactions.</p>
<disp-quote content-type="editor-comment">
<p>(4) The reported ability of CCDC32 to pull down AP2 beta is puzzling. Beta is not found in the CCDC32 interactome in two independent studies using 293 and HCT116 cells (BioPlex). In addition, clathrin is also absent in the interactome of CCDC32, which is difficult to reconcile with a proposed role in CCPs. Can the authors detect CCDC32 binding to clathrin?</p>
</disp-quote>
<p>Based on the studies of Wan et al. (PMID: 39145939), it is likely that CCDC32 binds to µ2, rather than to the b2 in the b2:µ2 hemicomplex.  As to clathrin being absent from the CCDC32 pull down, this is as expected since the interactions of clathrin even with AP2 are weak in solution (as shown in Figure 5C, clathrin is not detected in our AP2 pull down) so as not to have spontaneous assembly of clathrin coats in the cytosol. Rather these interactions are strengthened by both the reduction in dimensionality that occurs on the membrane and by avidity of multivalent interactions.  For example, Kirchausen reported that 2 AP2 complexes are required to recruit one clathrin triskelion to the PM.</p>
<disp-quote content-type="editor-comment">
<p>(5) Figure 5B appears unusual-is this a chimera?</p>
</disp-quote>
<p>Figure 5B shows an internal insertion of the eGFP tag into an unstructured region in the AP2 hinge. As we have previously shown (PMID: 32657003), this construct, unique among other commonly used AP2 tags, is fully functional.  We have rearranged the text in the Figure legend to make this clearer.</p>
<disp-quote content-type="editor-comment">
<p>Figure 5C likely reflects a mixture of immature and mature AP2 adaptor complexes.</p>
</disp-quote>
<p>This is possible, but mature heterotetramers are by far the dominant species, otherwise the 4 subunits would not be immuno-precipitated at near stoichiometric levels with the a subunit.  Near stoichiometric IP with antibodies to the a-AD have been shown by many others in many cell types.</p>
<disp-quote content-type="editor-comment">
<p>(6) CCDC32 is reduced by about half in siRNA knockdown. Why not use CRISPR to completely eliminate CCDC32 expression?</p>
</disp-quote>
<p>Fortuitously, partial knockdown was essential to reveal this second function of CCDC32, as we have emphasized in our Discussion.  Wan et al, used CRISPR to knockout CCDC32 and reveal its essential role as a AAGAB co-chaperone.  In the complete absence of CCDC32 mature AP2 complexes fail to form.  However, under our conditions of partial CCDC32 depletion, the expression of AP2 heterotetramers is unaffected revealing a second function of CCDC32 at early stages of CME.  We expect that the co-chaperone function of CCDC32 is catalytic, while its role in CME is more structural; hence the different concentration dependencies, the former being less sensitive to KD than the latter.  This is one reason that many researchers are turning to CRISPRi for whole genome perturbation studies as many proteins play multiple roles that can be masked in KO studies.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Public review):</bold></p>
<p>Yang et al. describes CCDC32 as a new clathrin mediated endocytosis (CME) accessory protein. The authors show that CCDC32 binds directly to AP2 via a small alpha helical region and cells depleted for this protein show defective CME. Finally, the authors show that the CCDC32 nonsense mutations found in patients with cardio-facial-neuro-developmental syndrome (CFNDS) disrupt the interaction of this protein to the AP2 complex. The results presented suggest that CCDC32 may act as both a chaperone (as recently published) and a structural component of the AP2 complex.</p>
<p>Strengths:</p>
<p>The conclusions presented are generally well supported by experimental data and the authors carefully point out the differences between their results and the results by Wan et al. (PNAS 2024).</p>
<p>Weaknesses:</p>
<p>The experiments regarding the role of CCDC32 in CFNDS still require some clarifications to make them clearer to scientists working on this disease. The authors fail to describe that the CCDC32 isoform they use in their studies is different from the one used when CFNDS patient mutations were described. This may create some confusion. Also, the authors did not discuss that the frame-shift mutations in patients may be leading to nonsense mediated decay.</p>
</disp-quote>
<p>As requested we have more clearly described our construct with regard to the human mutations and added the possibility of NMD in the context of the human mutations.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #3 (Public review):</bold></p>
<p>In this manuscript, Yang et al. characterize the endocytic accessory protein CCDC32, which has implications in cardio-facio-neuro-developmental syndrome (CFNDS). The authors clearly demonstrate that the protein CCDC32 has a role in the early stages of endocytosis, mainly through the interaction with the major endocytic adaptor protein AP2, and they identify regions taking part in this recognition. Through live cell fluorescence imaging and electron microscopy of endocytic pits, the authors characterize the lifetimes of endocytic sites, the formation rate of endocytic sites and pits and the invagination depth, in addition to transferrin receptor (TfnR) uptake experiments. Binding between CCDC32 and CCDC32 mutants to the AP2 alpha appendage domain is assessed by pull down experiments. While interaction between CCDC32 and the alpha appendage domain of AP2 is clearly described, a discussion of potential association with other AP2 domains would be beneficial to understand the impact of CCDC32 in endocytosis.</p>
</disp-quote>
<p>The reviewer is correct. That CCDC32 also interacts with other subunits of AP2, is evident from the findings of Wan et al. and by the fact that the CCDC32(D78-99) mutant efficiently co-IPs with the b2:µ2 hemicomplex.  We expanded our discussion around this point. CCDC32 remains an, as yet, poorly characterized, but we now believe very interesting EAP worth further study.</p>
<disp-quote content-type="editor-comment">
<p>Together, these experiments allow deriving a phenotype of CCDC32 knock-down and CCDC32 mutants within endocytosis, which is a very robust system, in which defects are not so easily detected. A mutation of CCDC32, mimicking CFNDS mutations, is also addressed in this study and shown to have endocytic defects.</p>
<p>In summary, the authors present a strong combination of techniques, assessing the impact of CCDC32 in clathrin mediated endocytosis and its binding to AP2.</p>
<p><bold>Recommendations for the authors:</bold></p>
<p><bold>Reviewer #2 (Recommendations for the authors):</bold></p>
<p>(1) The authors must be clear about the differences between the CCDC32 isoform they used in their manuscript and the one used to describe the patient mutations. This could be done, for example, in the methods. This is essential for the capacity of other labs to reproduce, follow up and correctly cite these results.</p>
</disp-quote>
<p>We have added this information to the Methods.</p>
<disp-quote content-type="editor-comment">
<p>(2) I believe the authors have misunderstood what nonsense mediated decay is. NMD occurs at the mRNA level and requires a full genome context to occur (introns and exons). The fact that a mutant protein is expressed normally from a construct by no means prove that it does not happen. I believe that adding the possibility of NMD occurring would enrich the discussion.</p>
</disp-quote>
<p>Thank you, we have now done more homework and have added this possibility into our discussion of the mutant phenotype.  However, if a robust NMD mechanism resulted in a complete loss of CCDC42 protein, then the essential co-chaperone function reported by Wan et al, would result in complete loss of AP2.  A more detailed characterization of the cellular phenotype of these mutations, including assessing the expression levels of AP2 would be informative.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #3 (Recommendations for the authors):</bold></p>
<p>- It is not clear what the authors mean by '~30s lifetime cohort' (line 159). They refer to Figure 2H, which shows the % of CCPs. Can the authors explain exactly what kind of tracks they used for this analysis, for example which lifetime variations were accepted? Do they refer to the cohorts in Figure S4? In Figure S4, the most frequent tracks have lifetimes &lt; 20 s (in contrast to what is stated in the main text). Why was this cohort not used?</p>
</disp-quote>
<p>The ‘30s cohort’ refers to CCPs with lifetimes between 25-35s which encompasses the most abundant species in control cells and CCDC32 KD cells, as shown by the probability curves in Figure 2H. Given the large number of CCPs analyzed we still have large numbers for our analyses n=5998 and 4418, for control and siRNA treated conditions, respectively.  Figure 2H shows the frequency of CCPs in cells treated with CCDC32 siRNA are shifted to shorter lifetimes. We have clarified this in the text.</p>
<disp-quote content-type="editor-comment">
<p>- Figure S1: It is now clear, why the mutant versions of CCDC32 are not detected in this western blot. However, data that show the resistance of these proteins to siCCDC32 is still missing (S1 A is in the absence of siCCSC32 I assume, as the legend suggests). A western blot using an anti-GFP antibody, as the one used in Figure S1, after siRNA knock-known would provide clarity.</p>
</disp-quote>
<p>That these constructs all contain the same mutation in the siRNA target sequence gives us confidence that they are indeed resistant to siRNA.</p>
<disp-quote content-type="editor-comment">
<p>- Note that the anti-CCDC32 antibody does not detect the eGFP-CCDC32(∆78-98) as well as full-length and is unable to detect eGFP-CCDC32(1-54)'. This phrase should belong to Figure S1 (B), not (A)</p>
</disp-quote>
<p>Corrected.</p>
<disp-quote content-type="editor-comment">
<p>- The immunoprecipitations of CCDC32 and its mutants with AP2 and its subunits are partially confusing. In Figure 5, the authors show that CCDC32 interacts specifically with the alpha-AD, but not with the beta-AD of AP2. In Figure 6B and C, on the other hand, Co-IPs are shown also with the beta and the mu domain of AP2. This is understandable in the context of the full AP2. However, when interaction with the alpha domain (and sigma) is abolished through mutation of helix 78-98, why would beta and mu still interact, when the beta-AD cannot interact with CCDC32 on its own. Are there interaction sites expected outside the ADs in the beta or mu domains?</p>
</disp-quote>
<p>See responses to reviewer 1 above.  This result likely reflects the co-chaperone activity of CCDC32 as reported by Wan et al it likely due to their reported interactions of CCDC32 with the µ2 subnit of b2:µ2 hemicomplexes.</p>
<disp-quote content-type="editor-comment">
<p>- Figure S6 D, E and F: How much confidence do the authors have on the AlphaFold predictions? Have the same binding poses been obtained repeatedly by independent predictions?</p>
</disp-quote>
<p>We provide, with a color scale, the confidence score for each interaction, which is very high (&gt;90%). Of course, this is still a prediction that will need to be verified by further structural studies as we have stated.</p>
</body>
</sub-article>
</article>